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CHAPTER 1 BACKGROUND AND SCOPE OF THE DISSERTATION 
1.1 Research motivation 
Vaccination holds great promise in the therapeutic treatment of cancer by 
leveraging the host’s immune system. Significant advances in cancer immunology have 
led to approval of the first therapeutic cancer vaccine by FDA.1 However, the development 
of cancer vaccines is still infant. Maximizing therapeutic efficacy while minimizing the side 
effects of cancer vaccines remains challenging. One of the major goals for 
immunotherapy is to reverse tumor-associated immunosuppression and to restore anti-
tumor immunity in patients. These challenges can be in part addressed through 
optimization of cancer vaccines, including formulation, rational design of antigen and 
vaccine adjuvants. 
Oligonucleotide-based therapeutics, including CpG ODNs (oligodeoxynucleotides), 
siRNA, aptamer and antisense have resulted in magnificent efficacy in the treatment of 
cancer over the past decades. However, one of the biggest barriers in the clinical 
application of these functional oligonucleotide-based therapeutics is the lack of efficient 
delivery. For example, CpG ODNs (single-stranded synthetic ODN molecules with 
unmethylated deoxycytidyl-deoxyguanosine) are potent immune adjuvants and can 
stimulate a wide range of immune cells in vitro. But their applications in vivo have been 
compromised mostly due to the lack of efficient delivery as well as their systemic toxicity. 
Targeting oligonucleotide-based vaccine adjuvants to lymph nodes and limiting the 
systemic dissemination have been shown to greatly improve both the efficacy and safety 
profiles.2,3 Recently, the ‘albumin-hitchhiking’ approach demonstrated a viable and 
attractive delivery strategy to achieve remarkable therapeutic efficacy and reduce 
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systemic toxicity.2 In this approach, a lipophilic lipid tail was covalently conjugated to CpG 
ODN and after subcutaneous injection, amphiphilic CpG ODN-adjuvanted vaccines 
accumulated in draining lymph nodes (dLNs), which harbored a great number of immune 
cells, and induced a 30-fold increase in antigen-specific cytotoxic CD8+ T cells in mice. 
Meanwhile, amphiphilic ODN conjugate dramatically reduced CpG-induced toxicity, 
overcoming the limitations of CpG ODNs in vivo. Here, we aim to further expand research 
scope of the “albumin-hitchhiking” approach in immune modulation by investigating the 
therapeutic efficacy of a variety of amphiphilic ODNs, and we also commit to developing 
novel adjuvants and drug-delivery strategies that would constitutively improve the 
immunogenicity of cancer vaccines and lead to tumor regression.  
1.2 Immunological background 
To understand how amphiphilic ODNs contribute to immune modulation, it is 
important to know how the immune system works. The immune system consists of a 
network of lymphoid organs and various immune cells including lymphocytes, dendritic 
cells, and natural killer cells. The immune system fulfills a pivotal role in defending the 
body against a wide variety of pathogens infections, including bacteria, virus and 
parasites, and in preventing the progression of cancer as well.4-6 The responses that the 
immune system mounts against foreign pathogens, allergies, self-damaged cells, and 
graft are called immune responses, which are generally classified into innate response 
and adaptive response. 
The innate immune response, which is nonspecific immune response, detects and 
recognizes foreign pathogens via PAMPs (pathogen-associated molecular patterns) that 
are evolutionarily conserved molecular motifs expressed by a variety of microbes.7,8 
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Innate immune cells, like professional antigen presenting cells (APCs) and phagocytes, 
detect and recognize PAMPs mainly through Toll-like receptors (TLRs) and other pattern 
recognition receptors (PRRs).7 Recognition of PAMPs leads to a cascade of signaling 
pathways and activates innate immune cells, triggering phagocytosis of pathogens and 
providing the first line of defense against various pathogens. Innate response induces 
rapid inflammation due to infection which gives rise to redness, swelling, heat, and pain. 
More importantly, innate response is crucial for the initiation of adaptive responses.7,8 
 
Figure 1-1. Schemes of how TLR ligands facilitate innate and adaptive immunity. 
The adaptive immune response, on the other hand, is a specific immune response. 
The adaptive immune response is primarily dominated by highly specialized lymphocytes 
including T cells and B cells. These specialized lymphocytes are activated by APCs that 
have completed phagocytosis and process of pathogens or pathogen-associated 
antigenic molecules. Once activated, these lymphocytes proliferate and differentiate into 
effector cells that specifically eliminate pathogens or suppress their growth and 
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proliferation. Other than specificity, another unique characteristic of adaptive immune 
response is immunological memory which forms and develops from an original adaptive 
immune response to a specific pathogen and can quickly induce a more potent immune 
response to the same pathogen in future encounters. Although it appears that adaptive 
immune response is more advanced and sophisticated than innate one, innate response 
is generally prerequisite to the activation of adaptive response which in return can 
enhance innate immunity by effector molecules such as cytokines and antibodies.7-9 The 
role of TLR ligands in bridging innate and adaptive immunity is illustrated in Figure 1-1. 
TLR ligands like CpG ODNs directly activate professional APCs, creating an immune 
milieu that is abundant in pro-inflammatory and T helper 1 (TH1)-type cytokines. By 
enhancing the function of professional APCs, TLR ligands can facilitate the development 
of humoral and cellular vaccine-specific immunity.10 
1.3 Scope of the dissertation 
 
Figure 1-2. Schemes of entry of lipo ODN into the lymphatics from interstitium. 
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In this dissertation, we focus on expanding the scope of the “albumin-hitchhiking” 
approach in immune modulation and aim to improve the therapeutic efficacy of cancer 
vaccines. The rationale of the “albumin-hijacking” approach is shown in Figure 1-2. Briefly, 
small-molecule drugs or moderately sized biomolecules less than 5 nm are preferentially 
absorbed from the interstitial space into the blood capillaries rather than lymphatic 
capillaries, while increasing molecular size leads to increasing uptake via the 
lymphatics.11 We mainly studied immunological roles and physiochemical properties of a 
variety of amphiphilic therapeutic molecules, including lipid-conjugated ODNs and PEG 
(polyethylene glycol) cargos, in modulating immune activation in vitro and in vivo. We first 
evaluated the efficacy of three representative classes of lipid-modified CpG ODNs as 
vaccine adjuvants. The results showed that lipid modification on CpG ODN enhanced 
cellular uptake in vitro and LN accumulation in vivo. Although lipid conjugation generally 
compromised immunostimulatory properties of CpG ODNs in vitro, administration of lipo 
CpG class B and C ODNs, not lipo CpG class A ODN, with a protein antigen in mice 
resulted in significantly improved antigen-specific CD8+ T cells responses and antibody 
responses. We then evaluated the therapeutic efficacy of immunosuppressive ODN A151 
and its lipid-modified form in suppressing TLR9-mediated immune responses in vitro and 
in vivo. The data demonstrated that lipo ODN A151 exhibited dramatically enhanced 
cellular uptake and increased LN accumulation compared to unmodified ODN A151. More 
importantly, tolerization with lipo ODN A151, not unmodified ODN A151 in mice, led to 
profound suppression of immune responses induced by CpG-adjuvanted vaccines. Next, 
we investigated the structure-based retention kinetics of lipid-based amphiphiles 
anchored on the plasma membranes of red blood cells (RBCs). We revealed that longer 
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lipid tail enabled more stable retention kinetics of amphiphiles anchored on RBCs, while 
shorter polyethylene glycerol (PEG) spacer was favored for markedly prolonged 
circulation half-life of amphiphiles inserted on RBCs in vivo. Furthermore, cationic 
amphiphiles covalently linked with cationic lipid tails demonstrated noticeably improved 
retention kinetics on RBCs in vivo compared to the anionic counterparts. Finally, we 
discovered a novel class of adjuvant booster that significantly enhanced the adjuvant 
potency of TLR7/8 agonists in vitro and in vivo. We found that lipid modification on several 
oligonucleotide-based TLR7 inhibitors led to remarkable upregulation of TLR7 agonist-
induced NF-κB activation in the presence of serum albumin. Notably, administration of 
imiquimod-adjuvanted vaccine laced with the structurally-optimized adjuvant booster in 
mice resulted in a five-fold increase in the frequency of antigen-specific CD8+ T cells and 
the production of antigen-specific IgG, in comparison with the same molecular vaccine 
without the adjuvant booster. 
In Chapter 2, we evaluated the immunostimulatory properties of amphiphilic CpG 
ODNs. Three representative classes of lipid-conjugated CpG ODNs were synthesized 
and their bioactivities as vaccine adjuvants were evaluated. We showed that lipid 
modification enhanced the stability of phosphodiester-backboned CpG ODN to nuclease 
degradation and the binding between albumin and CpG ODNs. In addition, the data 
revealed that lipid modification on CpG ODNs promoted cellular uptake and dramatically 
increased LN accumulation. Lipid-modified class A CpG (lipo CpG A) demonstrated 
improved stimulatory activities in murine TLR9 reporter cells and bone marrow-derived 
dendritic cells (BMDC) in vitro, while lipid modification on class B and C CpG ODNs 
decreased the level of TLR9-mediated NF-κB activation and reduced the production of 
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pro-inflammatory cytokines in BMDC. However, subcutaneous administration of a protein 
antigen ovalbumin (OVA) with lipo CpG B or CpG C, but not lipo CpG A, resulted in 
markedly improved OVA-specific IgG response and cytotoxic CD8+ T cell response in 
mice compared with unmodified CpG ODN-adjuvanted vaccines. Collectively, we showed 
that lipid modification on three representative classes of CpG ODNs differentially 
modulated immune responses in vitro and in vivo. This study highlighted the significance 
of in vivo LN-targeting delivery of CpG ODNs in improving their efficacy as vaccine 
adjuvants.  
In chapter 3, we investigated the therapeutic efficacy of lipid-modified 
immunosuppressive ODN A151 in inhibiting TLR9-mediated immune activation. 
Suppressive ODN A151 encoding TTAGGG motif can downregulate the production of 
pro-inflammatory and TH-1-biased cytokines, and therefore can markedly suppress TLR9 
agonist-induced immune responses in mice. We modified ODN A151 with an albumin-
binding diacyl lipid at its 5’-terminal. We found that lipid-functionalized ODN A151 showed 
increased cellular uptake and improved inhibitory capability of suppressing TLR9-
mediated immune activation in vitro, in comparison with unmodified ODN A151. More 
importantly, prophylactic treatment in mice with lipo ODN A151, but not unmodified ODN 
A151, led to a five-fold decrease in the frequency of antigen-specific CD8+ T cell and a 
significant reduction in the level of OVA-specific IgG in blood. Taken together, these 
findings suggested that targeting suppressive ODN to local LNs could be an effective 
approach to improving immune modulation. This approach might be utilized for treating 
autoimmune disorders with molecular immunomodulators.  
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In chapter 4, we analyzed the structure-dependent retention kinetics of lipid-based 
amphiphiles anchored on RBCs. We synthesized a variety of polymer amphiphiles with 
varying length of lipid tails and PEG spacers. Our results revealed that longer diacyl lipid 
chain conjugated amphiphiles exhibited more stable retention on RBCs, while shorter 
PEG spacers were favored for markedly prolonged circulation half-life of amphiphiles 
anchored on RBCs in vivo. In addition, we identified that blood flow-induced stress and 
serum albumin together played pivotal roles in the release of amphiphiles inserted on 
RBCs. Furthermore, cationic lipid modification on long PEG spacer strikingly extended 
the retention kinetics of amphiphiles anchored on RBCs in vivo and resulted in a 40-fold 
increase in circulation half-life in contrast to the anionic analogs. Our results highlighted 
the importance of molecular design in the dynamic stability of membrane-anchored 
amphiphiles.  
In chapter 5, we aimed to evaluate the therapeutic efficacy of lipid-modified 
oligonucleotide-based TLR7 inhibitors in treating systemic lupus erythematosus. 
However, we discovered that several lipid-modified oligonucleotide-based TLR7 inhibitors 
dramatically enhanced TLR7-mediated NF-κB activation rather than suppressed it. We 
then revealed that it was due to the presence of albumin that lipid modification 
transformed oligonucleotide-based TLR7 inhibitors into TLR7 adjuvant boosters. Besides, 
the data showed that these adjuvant boosters were applicable to human cells and could 
enhance human TLR7- and TLR8-mediated NF-κB activation. More importantly, 
subcutaneous administration of imiquimod-adjuvanted vaccine laced with the adjuvant 
booster in mice resulted in a five-fold increase in the expansion of antigen-specific CD8+ 
T-cells and enhanced antibody response relative to the same molecular vaccine without 
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the adjuvant booster. These findings highlighted a novel class of adjuvant booster which 
could be used to dramatically improve the immunogenicity of subunit vaccines and might 
be broadly applicable to current vaccines.   
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CHAPTER 2 IMMUNOSTIMULATORY PROPERTIES OF LIPID-MODIFIED CPG ODN 
2.1 Introduction 
Bacterial DNA containing the unmethylated CpG dinucleotides motifs (CpG motifs) 
in a specific sequence can stimulate mammalian immune cells.12-14 Synthetic 
oligonucleotides containing CpG motifs mimic molecular signatures of bacteria and can 
activate the vertebrate immune cells via TLR9.12 Discovered and developed in the early 
1990s, CpG ODNs have quickly drawn considerable interest due to the great promise of 
functioning as molecular adjuvants for vaccines. When co-administered with antigens, 
CpG ODNs activate professional APCs and subsequently augment antigen-specific 
humoral and cellular immune responses. Current clinical studies have shown that the 
utilization of CpG ODNs in human is safe and that CpG ODNs can improve the immune 
responses to co-administered antigens.10,13  CpG ODN directly stimulates B cells and 
dendritic cells (DCs), giving rise to the induction of both innate and adaptive immunity. 
TLR9 recognition is essential in this process. Once TLR9 is engaged by CpG ODNs, B 
cells produce IL-6, IL-12 and the CXCR3 chemokines IP-10, and secrete IgM, while DCs 
upregulate their expression of costimulatory molecules CD 40, CD86 and MHC 
molecules, and increase production of IL-1, IL-6, IL-12, IL-18, and TNF-α.15 Meanwhile, 
DCs differentiate to a mature stage where the antigen-presenting function is enhanced, 
which in turn, promotes the generation of humoral and cellular vaccine-specific immunity. 
Hence, CpG ODN creates an immune milieu where proinflammatory and TH1-type 
cytokines are enriched. Moreover, this innate immune response lays a solid foundation 
for antigen-specific adaptive immunity.10 
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CpG ODNs trigger the secretion of TH1-type and proinflammatory cytokines and 
stimulate the maturation of professional APCs. These immunological effects promote the 
usage of CpG ODNs as potential vaccine adjuvants or “danger signal” to enhance the 
immunogenicity of co-administered antigens. To date, a variety of CpG ODNs have been 
utilized to elicit an innate immune response through the TLR9 activation pathway.10,16,17 
Afterwards, innate immune responses can lead to the proliferation of cytotoxic CD8+ T 
cells and enhance the antigen-specific adaptive immune response against tumor 
antigens.10,16,17 Several preclinical studies have been carried out in mice to examine the 
immunogenicity of CpG-adjuvanted vaccines, and it is established that CpG ODNs are 
adequate to promote the humoral and cellular immune response to proteins such as 
ovalbumin.18,19 Several clinical studies have also exploited CpG ODNs in a combination 
of cancer vaccines. In melanoma studies, patients immunized with CpG ODN-adjuvanted 
vaccines developed >3% of circulating CD8+ T cells that were Melan-A-specific. That was 
an order magnitude greater than subjects treated with vaccine alone.20 In addition, in 
studies of Energix B, CpG ODN-adjuvanted vaccine induced a more potent and rapid 
antibody response. Specifically, subjects treated with CpG ODN-adjuvanted vaccine 
resulted in 13-fold greater primary and 45-fold greater secondary serum IgG Ab 
responses than those immunized with vaccine only.21,22 Collectively, CpG ODNs function 
as excellent adjuvants for cancer vaccines and bioagents for therapeutic treatment.  
However, one of the major barriers to extensively utilize CpG ODNs as vaccine 
adjuvants in clinical application is lack of efficient delivery to APCs in secondary lymph 
organs, such as lymph nodes.2,23,24 In addition, CpG ODNs bridged by phosphodiester 
(PO) are vulnerable to rapid degradation by DNase. As a result, DNase-resistant CpG 
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ODNs synthesized by chemical modification with phosphorothioate (PS) backbone are 
widely studied in vivo.10,16,17 However, significant obstacles stand because of inadequate 
accumulation of CpG ODN in the immune system and incompetence of CpG ODN to 
penetrate cellular membranes. Regardless of its desirable nucleases resistance, CpG 
ODN cannot be readily internalized by APCs after parental immunization due to its small 
size, negative charge, and hydrophilic backbone. Recently, we showed that lipid 
conjugation at 5’ terminal of class B CpG ODN significantly promoted its cellular uptake 
and accumulation in APCs in LNs after subcutaneous injection.2 Lipid conjugated CpG 
ODN  tightly bound to endogenous albumin and abundantly trafficked to draining LNs 
where it was physiologically filtered and accumulated in the APCs. This approach 
remarkably improved systemic safety as well as therapeutic efficacy of class B CpG ODN 
as vaccine adjuvant.2 Based on their intrinsic sequences, structural characteristics, and 
biological activities, CpG ODNs can be classified into three representative types.10,16 
These classes of CpG ODNs contain a complete or partial PS backbone and a poly-G tail 
at either 3’ or 5’ end, or both ends, and demonstrate structure-based immunostimulatory 
properties.10,16 However, whether lipid modification can augment the biological activities 
of all three classes of CpG remains unclear. Here we aim to evaluate the immune 
stimulatory properties of all three classes of lipid-tagged CpG conjugates (lipo CpG) in 
vitro and in vivo, with an emphasis on their adjuvant activities when co-administered with 
a protein antigen. Our data confirmed that lipo CpG was able to function as a safe 
adjuvant and induced robust antigen-specific immunity evidenced by potent cytotoxic T 
cell and humoral responses. In addition, our data clearly suggested the in vitro 
immunostimulatory activities of CpG did not suffice to reproduce in vivo vaccine efficacy. 
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2.2 Materials and methods 
2.2.1 Synthesis of diacyl lipid phosphoramidite  
The diacyl lipid phosphoramidite was synthesized as previously described.2 A 
solution of stearoyl chloride (6.789 g, 22.41 mmol) in 1,2-dichloroethane (50 mL) was 
added dropwise to a solution of 1,3-diamino-2-dydroxypropane (1.0 g, 11.10 mmol) in the 
presence of 1,2-dichloroethane (100 mL) and triethylamine (2.896 g, 22.41 mmol). The 
reaction mixture was stirred for 2 h at 25 °C and then heated at 70 °C overnight. The 
reaction mixture was then cooled to 25 °C, filtered, and the solid was sequentially washed 
with CH2Cl2, CH3OH, 5% NaHCO3 and diethyl ether. The product was dried under vacuum 
to give the intermediate product as a white solid (yield: 90%). 1H NMR (300 MHz, CDCl3, 
ppm): δ 6.3 (m, 2H), 3.8 (m, 1H), 3.4-3.2 (m, 4H), 2.2 (t, 4H), 1.6 (m, 4H), 1.3-1.2 (m, 
60H), 0.9 (t, 6H). The intermediate product (5.8 g, 9.31 mmol) and N, N-
Diisopropylethylamine (DIPEA, 4.2 mL, 18.62 mmol) was then suspended in anhydrous 
CH2Cl2 (100 mL). The mixture was cooled on an ice bath and 2-Cyanoethyl N, N-
diisopropylchlorophosphoramidite (8.6 mL, 0.47 mmol) was added dropwise under dry 
nitrogen. After stirring at 25 °C for 1 hour, the solution was heated to 60 °C for 90 min. 
The solution was washed with 5% NaHCO3 and brine, dried over Na2SO4 and 
concentrated under vacuum. The final product was isolated by precipitation from cold 
acetone to afford 4 g (55% yield) lipid phosphoramidite as a white solid. 1H NMR (300 
MHz, CDCl3): δ 6.4 (m, 2H), 3.9 (m, 2H), 3.8 (m, 2H), 3.6 (m, 2H), 3.0-2.9 (m, 2H), 2.6 (t, 
2H), 2.2 (m, 4H), 1.6 (m, 6H), 1.3-1.2 (m, 72H), 0.9 (t, 6H). 31P NMR (CDCl3): 154 ppm. 
2.2.2 Synthesis and purification of oligonucleotides  
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All ODN sequences were synthesized using an ABI 394 DNA synthesizer on a 1.0 
micromole scale. All lipophilic phosphoramidites were conjugated as a final ‘base’ on the 
5’ end of oligos. Lipophilic phosphoramidite was dissolved in dichloromethane and 
coupled to oligos in DNA synthesizer (15min coupling time). After the synthesis, DNA was 
cleaved from the solid support, deprotected, and purified by reverse phase HPLC using 
a C4 column (BioBasic-4, 200mm x 4.6mm, Thermo Scientific), 100mM triethylamine-
acetic acid buffer (TEAA, pH 7.5)-methanol (0-5min, 50-80%; 5-15min, 80-100%) as an 
eluent. Lipophilic ODNs typically eluted at 13min while unconjugated oligos eluted at 
7min. Fluorescein label ODNs were synthesized using 3’-(6-Fluorescein) tagged 
controlled pore glass. Lipid-conjugated CpG ODN 158525 (Class A CpG: 5'-
ggGGTCAACGTTGAgggggg-3’), CpG ODN 182626 (Class B CpG: 5’-
tccatgacgttcctgacgtt-3’), CpG ODN 239527 (Class C CpG: 5'-tcgtcgttttcggcgcgcgccg-3’) 
(lower case letters indicate phosphorothioate linkage; capital letters refer to 
phosphodiester linkage) were synthesized using the above method.  
2.2.3 DNase I protection assay  
To evaluate the role of lipid modification in protecting CpG ODNs, three classes of 
free CpG ODNs and their lipid-modified counterparts were incubated in the presence of 
the DNase I (0.5 unit per μg of ODN) at 37 ℃. At different time points, aliquots of these 
samples were collected and were immediately added 2 μL of EDTA (0.5 M) to stop DNase 
degradation. Samples were stored at -20 ℃ until subjected to gel electrophoresis 
analysis. The integrity of the ODNs in each formulation was compared with untreated 
ODNs as a control. The ODN’s stability was further evaluated in freshly isolated mouse 
serum. 30 µM free or lipid conjugated CpG A, B, and C (fluorescein labeled at 3’-end) 
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were incubated with or without 5 µL mouse plasma serum in PBS (1 X) with a final volume 
of 25 µL at 37 ℃ for 8 h. After incubation, 2.5 µL aliquot mixture of each sample was 
aspirated to a vial containing 6.5 µL TBE buffer (1X) and 1 µL glycerol. Electrophoresis 
was run in 1% agarose gel at 75 V for 10 min, and then the gel was photographed under 
UV. 
2.2.4 Albumin binding assay  
We used a gel electrophoresis mobility shift assay28 to detect albumin protein 
complexes with nucleic acids. Solutions of different concentrations of albumin protein and 
fluorescein-labeled CpG ODNs in different formulations were combined and incubated in 
PBS at 37 ℃ for 2h, the resulting mixtures are subjected to electrophoresis under native 
conditions through 1% agarose gel. The dissociation constant (Kd) values were estimated 
by using ImageJ software (NIH) to quantitate the fluorescent signal in each ODN band.28 
Background signals from blank regions of the gel were subtracted from the signal 
intensities obtained from bands. The fraction of ODN bound was determined from the 
background-subtracted signal intensities using the expression: bound/total ODN. The 
fraction of ODN bound in each reaction was plotted versus the concentration of albumin. 
The data were fit with the following binding equation using GraphPad Prism software to 
perform non-linear regression and obtain a value for Kd. 
2.2.5 In vitro DC uptake and confocal imaging  
DC2.4 cells were cultured with RPMI-1640 supplemented with 10% FBS and 1% 
P/S; and were incubated with 1 µM fluorescein-labeled free or lipid-modified CpG A, B, 
and C at 37 ℃ for 4 h. After incubation, cells were washed twice with PBS by centrifuge 
at 800X g for 5 min prior to flow cytometry quantification. To visualize in vitro cellular 
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uptake, DC2.4 cells were cultured and incubated again under the same experimental 
conditions and were subjected to confocal imaging by Zeiss LSM 510 microscope. 
2.2.6 In vitro TLR reporter cells stimulation  
HEK-Blue™-mTLR9 and RAW-BlueTM cells were purchased from InvivoGen and 
were used to evaluate CpG ODN’s adjuvant activities in vitro. 0.5µM CpG formulations 
were added to InvivoGen HEK-Blue™ murine TLR9 or RAW-Blue™ mouse macrophage 
reporter cell lines, both of which are engineered with secreted embryonic alkaline 
phosphatase (SEAP) reporter system. After 24h incubation, SEAP levels were quantified 
by developing supernatant with QuantiBlue™ substrate for 1h and reading absorption at 
620 nm, following the manufacturer’s instructions.  
2.2.7 In vitro Bone Marrow Dendritic Cells stimulation  
Bone marrow-derived dendritic cells (BMDCs) were generated by following the 
previous protocol, with minor changes.29 Briefly, bone marrow was flushed from femurs 
and tibia of C57BL/6 mice (5-6 weeks) and plated at 5×105 cells/ml in complete RPMI 
plus 5ng/ml recombinant murine GM-CSF. On day 3 and day 5, half of the culture volume 
was replaced with fresh complete RPMI + GM-CSF. On day 8, BMDCs were harvested 
and were stimulated with 0.5µM immunostimulatory CpG ODNs for 24h. The inflammatory 
cytokines secreted by BMDCs, including IL-6, IL-12, and TNF-α, were measured by 
ELISA (enzyme-linked immunosorbent assay).  
2.2.8 Lymph node imaging and cellular uptake  
Groups of C57BL/6 (n=4 Lymph nodes/group) were injected subcutaneously at the 
tail base with 3nmol of fluorescein-labeled free CpG or lipo-CpG of class A, B, or C. After 
24h, animals were sacrificed and inguinal and axillary LNs were excised and imaged 
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using In-Vivo Xtreme (Bruker) imaging system. LNs were then digested with 1.5mL of 
freshly prepared enzyme mixture comprised of RPMI-1640 containing 0.8mg/mL 
Collagenase/Dispase (Roche Diagnostics) and 0.1mg/mL DNase (Roche Diagnostics) 
and LN cells were stained with antibodies against F4/80 and CD11c versus CpG 
fluorescence in viable cells. Percentages of CpG+ cells in the LNs were determined by 
flow cytometry. 
2.2.9 In vivo immunization with immunostimulatory ODN  
C57BL/6 mice (6-8 weeks) were vaccinated by a homologous prime-boost 
regimen: animals were primed on day 0 and boosted on day 14 (unless stated otherwise) 
with 10µg Ovalbumin and 1.24nmol CpG (in unmodified or in lipid-modified forms) 
dissolved in PBS. The volume of all vaccine injections was 100 µL/animal. All injections 
were performed subcutaneously at the base of the tail.  
2.2.10 Tetramer Staining  
Seven days after the final immunization, blood samples were collected. Red blood 
cells were lysed by ACK lysing buffer. Cells were then blocked with Fc-blocker (anti-
mouse CD16/CD32 monoclonal antibody) and stained with SIINFEKL loaded 
phycoerythrin-labeled tetramers (Beckman Coulter) and anti-CD8-APC (ebioscience) for 
30min at 4oC. Cells were washed twice, resuspended in FACS buffer, and analyzed on 
Attune Focus flow cytometer. Analysis typically gated on live CD8+, Tetramer positive 
cells. 
2.2.11 ELISA for OVA-Specific IgG  
Mice blood samples were collected. Serum anti-OVA IgG levels were determined 
by ELISA: 96-well plates were coated overnight with 10μg/ml OVA in PBS and blocked 
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with 1% BSA in PBS. After incubation of serum samples for 1h at a series of dilutions, 
plates were washed with PBS/1% Tween-20. Goat anti-mouse IgG conjugated to 
Horseradish peroxidase (HRP) was added at 1 μg/ml for 30min. Plates were washed with 
PBS/1% Tween-20 and ELISA was developed by (3,3’,5,5’-Tetramethylbenzidine) (TMB, 
ebioscience). The reaction was stopped by 1M H2SO4 and the absorbance was read at 
450 nm and 570 nm using a plate reader. 
2.2.12 Statistical analysis  
All plots show mean values and error bars represent the SEM. Comparisons of the 
mean values of two groups were performed using unpaired Student’s t-tests. One-way 
analysis of variance (ANOVA), followed by a Bonferroni post-test was used to compare 
>2 groups. *, p<0.05; **, p<0.01; ***, p<0.001; ns, not significant unless otherwise 
indicated. Statistical analysis was performed using GraphPad Prism software (San Diego, 
CA). 
2.3 Results and discussion 
2.3.1 Lipid modification enhances phosphodiester CpG ODN’s stability in vitro  
The ability of chemical modification to protect oligonucleotides from nuclease 
degradation is an important property for efficient immunostimulation. CpG ODN must be 
protected from nuclease digestion for maximal activity in vivo. To test whether the lipid 
modification improves the ODN’s stability, all three classes of CpG ODNs were incubated 
with DNase I at 37 °C. CpG A contains a core sequence with phosphodiester backbone 
and a few nucleases resistant phosphorothioate (PS) poly-G blocks at both ends.25 
Despite a partial PS backbone stabilization, CpG A ODN is still susceptible to nuclease 
degradation, as shown by the complete disappearance of the CpG band illustrated in the 
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gel-electrophoresis 16 hours after incubation (Figure 2-1 (a)). However, 5’-lipid 
conjugation protects the CpG A ODN from DNase I degradation, showing a nearly intact 
band after 24h incubation (Figure 2-1 (a)). The stability of full phosphorothioate CpG B 
and CpG C ODN were unaffected in the presence of DNase I (Figure 2-1 (b) and (c)). 
Thus, lipid conjugation does not further improve its enzymatic stability.  
 
Figure 2-1. (a-c), CpG A, B, C, and their lipid conjugated formulations were 
incubated with DNase I and their stability were analyzed using incubation times of 1, 2, 
3, 15, and 21 hours. (d-f), Measurement of the albumin binding by gel shift assay. 15 
μM of CpG ODNs were incubated with different concentrations of albumin (15, 50, 100, 
200, 300, 400, and 600 µM) in PBS for 2 h at 37 °C, sample aliquots were analyzed by 
agarose gel electrophoresis. The binding of albumin induces a motility shift in CpG 
ODNs. 
Covalent conjugation or noncovalent interaction with albumin has been shown to 
extend the half-life of shortly-lived oligonucleotides.30 Albumin functions as the main 
fatty acid binding protein in extracellular fluids.31 Thus, lipid conjugation might facilitate 
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the binding between albumin and CpG ODN and improve their enzymatic stability. We 
used a gel mobility shift assay to visualize the interaction between three classes of CpG 
ODNs and albumin protein. As shown in Figure 2-1 (d-f), when different classes of CpG 
ODNs were titrated with purified albumin protein, unmodified CpG ODN showed sharp 
trailing bands only at high albumin concentrations. This is most likely due to the low 
affinity, non-specific interaction between the PS backbone modification and albumin 
protein.32-35 Phosphorothioate modification of inter-nucleoside linkage is known to 
induce non-specific protein binding. The binding was demonstrated to be sequence- 
and protein-independent and correlated with the extent (number of PS bonds) of the PS 
modification. In contrast, lipo CpG ODN bound to albumin protein at low concentration 
via the lipid-albumin interaction. We estimated the equilibrium dissociation constant (Kd) 
between 75 µM-100 µM for unmodified CpG ODNs.16 These values are consistent with 
previous reports but are nearly 1000 times higher than the Kd of lipid-modified CpG (ca. 
100 nM).9  
 
Figure 2-2. CpG’s serum stability assayed by agarose gel. 30 µM free or lipid 
conjugated CpG A, B, and C (fluorescein labeled at 3’-end) were incubated with or 
without 5 µL mouse plasma serum in PBS (1X) with a final volume of 25 µL at 37 °C for 
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8h. Samples were subjected to agarose gel electrophoresis and subsequently 
photographed under UV. 
Similar stability results were obtained when CpGs were incubated with freshly 
isolated mouse serum (Figure 2-2). Taken together, these data showed that lipid 
modification enhanced the binding between CpG and albumin and improved the CpG’s 
stability in vitro. 
2.3.2 Lipid modification on CpG enhances cellular uptake  
 
Figure 2-3. Three classes of CpG ODNs and their lipid-modified forms were 
incubated with DC2.4 cells for 4 hours at 37 °C. Cells were washed and were subjected 
to laser scanning confocal microscopy imaging for intracellular distribution (a) showing 
representative class B CpG and flow cytometry analysis for quantification of cellular 
uptake (b). Scale bar: 10 μm. Data show the mean values ± SEM. *, p < 0.05; **, p < 
0.01; ***, p < 0.001; ****, p < 0.0001 by one-way ANOVA with Bonferroni post-test. 
The accumulation of FAM-labeled CpG ODNs and their lipophilic conjugates in 
DC2.4 cells was measured using flow cytometry and confocal microscopy after 4 hours 
of incubation with the corresponding CpGs. As expected, DC2.4 cells (a murine dendritic 
cell line) treated with 1µM lipid-modified CpG showed a 2~5-fold increase than their 
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unmodified counterpart after 4h incubation, independent of CpG type (Figure 2-3). Flow 
cytometry analysis suggested that class B and C CpG ODNs exhibited higher cellular 
fluorescence compared with CpG A (Figure 2-3 (b)), possibly because of their improved 
enzymatic stability. Confocal microscopy analysis showed similar intracellular 
distributions of free CpG and lipo CpG for all three classes, most of which were confined 
in intracellular membrane structures, including endosomes, where TLR9 is expressed. 
Thus, we confirmed that in vitro, lipid modification greatly enhanced the uptake of CpG 
ODNs but did not alter their intracellular distributions.  
2.3.3 Adjuvant activities of lipid-modified CpG in vitro 
 
Figure 2-4. Three classes of CpG ODNs and their lipid-modified forms (1 μM) were 
incubated with HEK mTLR9 cells, which secrete SEAP upon TLR9 stimulation (a) or Raw-
Blue mouse macrophage reporter cells, which secrete SEAP upon multiple TLR, NOD or 
Dectin-1 stimulation (b), SEAP levels were quantified by incubating supernatant with 
QuantiBlue substrate for 1 h and reading absorption at 620 nm. (c-e), Bone-marrow-
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derived immature dendritic cells were incubated overnight with 0.5 µM of CpG 
formulations, the inflammatory cytokines secreted by BMDCs, including IL-12 (c), IL-6 (d) 
and TNF-α (e), were measured by ELISA (enzyme-linked immunosorbent assay). Data 
show the mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; 
ns, not significant by one-way ANOVA with Bonferroni post-test. 
The adjuvant activities of the lipid-modified CpG were first examined in vitro. 
Murine TLR9 reporter cells, which were co-transfected with murine TLR9 gene and an 
inducible SEAP (secreted embryonic alkaline phosphatase) reporter gene, were 
incubated with lipid-modified CpG ODNs, using their unmodified counterparts as controls. 
CpG A induced a low but detectable level of TLR9 stimulation in murine TLR9 cells 
(Figure 2-4 (a)). Lipid-modified CpG A significantly enhanced the TLR9 stimulation 
(Figure 2-4 (a)), as shown by increased SEAP production at 500nM CpG for 24h 
incubation, suggesting lipid conjugation does not compromise the TLR9 stimulation for 
class A CpG. However, it is believed the accessibility of 5’-terminal of B and C class CpG 
oligonucleotide is important for receptor recognition and subsequent immune 
stimulation.36 Chemical modification on 5’ terminal thus has been shown to abrogate B 
class CpG’s stimulatory activities in vitro.37 Consistent with the previous report, the 
immune stimulatory activities of the lipid-modified class B and C CpG ODNs were 
significantly reduced when compared with SEAP secretion induced by the unmodified 
CpGs (Figure 2-4 (a)). The CpG type-dependent immune modulation was also 
demonstrated in RAW-BlueTM mouse macrophage reporter cells (Figure 2-4 (b)), which 
secreted SEAP upon multiple TLRs, NOD or Dectin-1 stimulation. TLR stimulation is 
known to stimulate DC to produce higher levels of multiple cytokines which directly impact 
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DC function.38 The ability of lipo CpG to induce the production of inflammatory cytokines 
such as IL-12, IL-6 and TNF-α were evaluated in bone marrow-derived dendritic cells 
(BMDCs). Following incubation, CpG A-induced an elevated level of the TNF-α but not 
IL-12 and IL-6 (Figure 2-4 (c-e)). The lipid-modified CpG A potentiated the TNF-α 
production as compared to unmodified CpG A. However, lipid modification on CpG A had 
no effect on IL-12 and IL-6 levels (Figure 2-4 (c-e)). Like the TLR reporter cell results, 
lipid modification on class B and C CpG ODNs reduced the IL-12, IL-6 and TNF-α 
production by 2-3-fold, though all the cytokines were still detectable (Figure 2-4 (c-e)). 
Together, these data demonstrated that lipid modification modulated CpG immune 
activities in a CpG class dependent manner. Lipid modification augmented the adjuvant 
activity of CpG A but compromised that of class B and C CpG in vitro.  
2.3.4 Lipid-modified CpG accumulates in LNs and abrogates CpG-induced toxicity 
in vivo  
Lipid-modified CpG binds to albumin and accumulates in draining lymph nodes 
after s.c. injection.2 Such site-specific accumulation also reduces the systemic exposure 
of CpG. Systemic exposure of CpG ODN is known to generate non-specific immune 
activation, characterized by lymphocyte proliferation in the spleen and release of 
proinflammatory cytokines.39 The lymph node accumulation of all three classes of CpGs 
and their lipid conjugates were tested in C57BL/6 mice. Mice were injected with 
fluorescein-labeled CpG in original or in lipid-conjugated forms. 24h post-injection, both 
inguinal and axillary lymph nodes were isolated and imaged. Both lipo CpG B and lipo 
CpG C showed dramatically enhanced accumulation in inguinal and axillary nodes 
(Figure 2-5 (a-b)) when compared with class B and C CpG ODNs, respectively. In 
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contrast, the overall accumulation of lipo CpG A and CpG A remained low and no 
statistical difference was observed between these two groups (Figure 2-5 (a-b)). To 
determine the immune cell uptake of CpG, lymph nodes were digested, and cells were 
analyzed by flow cytometry after antibodies staining to identify the specific immune cells. 
Unmodified CpGs exhibited less uptake in CD11c+ DCs and F4/80+ macrophages, the 
key antigen presentation cells in the lymph nodes. In contrast, lipid modification enhanced 
the cellular uptake by 2-4 folds, though some fluctuations were observed in the inguinal 
nodes in mice injected with class A CpG (Figure 2-5 (c-e)). Overall, these results clearly 
showed lipid modification on CpG ODNs enhanced their lymph node accumulation and 
immune cell uptake. Among these three types of CpG ODNs we tested, lipo CpG A 
exhibited a modest enhancement in lymph node retention. This might be explained by 
relatively low stability of class A CpG in vivo. In contrast, lipid modification dramatically 
increased the lymph node accumulation of PS backbone-stabilized class B and C CpG.  
To test whether lipid modification could reduce the systemic toxicity of CpG, mice 
received 3 injections of CpG (1.24 nmol on day 0; 2.48 nmol each on day 2 and day 4) 
and their spleens were excised and analyzed for splenomegaly, a common feature of 
CpG ODN driven systemic immune activation in mice. Neither CpG A nor lipo CpG A-
induced splenomegaly, showing spleen weights indistinguishable from PBS control 
(Figure 2-5 (f)). Mice injected with CpG B induced a nearly 1.5-fold increase in spleen 
weight, indicating a systemic exposure of CpG B.2,39 However, lipid modification on class 
B CpG ODN markedly alleviated the acute splenomegaly in mice, suggesting a minimized 
systemic exposure of class B CpG ODN after lipid modification (Figure 2-5 (f)). 
Interestingly, both free CpG C and lipo CpG C treated mice showed no noticeable sign of 
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splenomegaly when contrasted with the effect of class B CpG ODN (Figure 2-5 (f)), 
suggesting this type of CpG could be safer than CpG B in mice. This data was consistent 
with previous findings that lipid conjugated CpG ODNs accumulated in the draining lymph 
nodes and reduced systemic exposure.2 
 
Figure 2-5. Mice (n=4 lymph nodes/group) were injected s.c. at the tail base with 
3.3 nmol fluorescein-labeled class A, B, and C CpG or lipo-CpG. Inguinal LNs (proximal 
nodes) and axillary LNs (distal nodes) were isolated 24 hours post-injection and CpG 
accumulation in nodes was imaged (a) and quantified (b) by using In-Vivo Xtreme (Bruker) 
imaging system. (c-e), lymph nodes were digested, and lymph nodes cells were stained 
with DAPI and antibodies against F4/80, CD11c. Shown are representative flow cytometry 
plots of CD11c staining and F4/80 staining (c) versus CpG fluorescence in viable (DAPI-) 
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cells. Percentages of CpG+ cells in the LNs determined by flow cytometry at 24 hr (d, e).  
(f), Splenomegaly in mice (n=3/group) assessed on day 6 after 3 injections of CpG (1.24 
nmol on d0, 2.48 nmol each on d2 and d4). Data show the mean values ± SEM. *, p < 
0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by one-way ANOVA 
with Bonferroni post-test. 
2.3.5 Lipid modification on class B and C CpG ODNs, but not on class A CpG 
ODN, dramatically enhance immunogenicity of molecular vaccines 
 
Figure 2-6. C57Bl/6 mice (n=4/group) were immunized with ovalbumin (10 µg) + 
CpG (1.24 nmol) on d0 and d14. Six days after the final immunization, mice were bled 
and antigen-specific T-cell responses in peripheral blood were evaluated by SIINFEKL 
tetramer assay. Shown are representative flow cytometric dot plots of H-2Kb/SIINFEKL 
tetramer staining of CD8+ cells (a) and quantification (b).  (c), at d 20, serum samples 
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were collected and assayed by ELISA for anti-OVA IgG production. Data show the mean 
values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant 
by one-way ANOVA with Bonferroni post-test. 
The in vivo activities of lipid-modified CpG ONDs as vaccine adjuvants were 
evaluated in C57BL/6 mice. CpG ODN has been widely studied to improve both humoral 
and cellular immune responses in animals.10,16,17 Mice were immunized subcutaneously 
on day 0 and day 14 with 10μg Ovalbumin (OVA) protein antigen adjuvanted by 1.24nmol 
CpG ODNs in original or in lipid conjugates formulations. OVA was simply mixed with 
CpG ODNs and was not associated with CpG or lipo-CpG. No OVA-specific CD8+ T cells 
and anti-OVA IgG antibody above the baseline were detected in mice immunized with 
class A CpG (Figure 2-6).  
Despite the enhanced serum stability as well as TLR9 stimulation in vitro, lipid-
modified CpG A did not enhance the frequency of OVA-specific CD8+ T cells in blood, 
showing an average of 5.4% comparable with those with OVA alone. However, in mice 
immunized with lipo CpG B or lipo CpG C, nearly 16% and 22% of the blood CD8+ T cells 
were specific for the MHC-I-restricted peptide OVA257-264, respectively (Figure 2-6 (a-b)). 
These frequencies were markedly improved when compared to mice immunized with 
unmodified class B and C CpG ODNs. These results were in contrast with the stimulatory 
activities of lipo CpG B and lipo CpG C in vitro, where a 2-3-fold reduction of activities 
was observed. Furthermore, lipo CpG B and lipo CpG C rapidly potentiated the 
development of an OVA-specific IgG response as compared to their unmodified 
counterpart (Figure 2-6 (c)). In mice immunized with OVA together with CpG A or lipo 
CpG A, no increase in OVA-specific IgG was seen compared with mice immunized with 
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OVA alone. We thus concluded that lipid modification on CpG B and CpG C, but not on 
CpG A, efficiently enhanced CD8 T cell and B cell responses to a protein antigen in vivo. 
Unmethylated cytosine-phosphate-guanosine (CpG) dinucleotide is recognized by 
TLR9 and induces immune system activation.12-14 Immunostimulatory activities of CpG 
were first discovered when a DNA from Bacille Calmette-Guerin was found to stimulate 
the production of type I interferon.29 Since then, synthetic immunostimulatory 
oligonucleotides containing CpG motifs have been widely used as vaccine adjuvant 
because these ODNs were stable against enzymatic digestion, and were capable of 
stimulating a wide variety of immune cells.10,16,17 To date, however, the in vitro promise of 
CpG has not been translated to in vivo primarily due to limited therapeutic efficacy and 
safety concerns.17 When used as a vaccine adjuvant, CpG must reach LNs, the anatomic 
site where all the immune cells interact with each other. Attempt to enhance the lymph 
node delivery of CpG has included the nanoparticulate materials.23,24 However, it remains 
difficult to design nanocarriers which meet all the criteria for in vivo LNs targeting.40,41 
Most of the current nanoparticles do not fulfill clinical demands primarily due to 
requirements for complex designs including surface engineering to reduce non-specific 
tissue interactions, structural modification to enhance CpG encapsulation and incorporate 
ligands to maintain immune cells targeting.41 Possible stability, toxicological issues also 
restrict the nanocarrier’s clinical application in the short-term.42-44 Thus, a molecular 
approach would be more attractive.  
Previously we developed a lipo CpG conjugation approach which targeted the CpG 
to the draining LNs via an albumin-mediated mechanism.2 Structurally optimized lipo CpG 
conjugate binds to endogenous albumin and subsequently transports to the draining LNs. 
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Albumin binding dramatically increased CpG ODN’s hydrodynamic size, prevented it from 
diffusing into blood circulation, and retargeted it to the lymphatics. However, only class B 
CpG was investigated. CpG ODNs have been divided into three major classes (A, B and 
C types) based on their sequences, structural characteristics and immunological activities, 
so it is important to evaluate the immunostimulatory activities of each CpG class after lipid 
modification. Although additional classes of immunostimulatory ODNs have been 
described, of great interest are the recently discovered P-type and S-type ODNs which 
have been recently discovered and not been utilized extensively.  The present study 
describes in vitro and in vivo immunostimulatory activities of three representative 
sequences derived from different types of CpG ODNs after lipid modification. Lipid 
modification at 5’-end of all three classes of CpG greatly enhanced their cellular uptake 
in vitro. Class A CpG, which contains palindromic CpG phosphodiester sequences with 
phosphorothioate G-rich ends, lacks the stability in vitro and in vivo. Subsequent lipid 
conjugation enhanced class A CpG’s stability and immunostimulatory activities in vitro. 
However, the ability of class A CpG to boost the humoral and cellular immune responses 
in vivo remains limited, as no potent immune responses were observed in both 
unmodified and lipid conjugated class A CpG ODNs when combined with a protein 
antigen. Outstanding responses to antigen have been reported in a variety of studies 
using class B CpG as an adjuvant.10,16,17 Our results demonstrated that lipid modification 
on both class B and C CpG, contrasted with class A CpG, acted as very potent TH-1-
promoting adjuvants in mice, although lipid modification appeared to greatly compromise 
their immunostimulatory activities in vitro. The observed difference between the activities 
in vitro and in vivo might be explained by increased LN accumulation and APC uptake in 
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vivo, however, current studies cannot rule out the existence of other mechanisms 
independent of lymphatic system targeting. One possible explanation could be CpG 
adjuvant’s kinetic in terms of LN accumulation. Interestingly, despite dramatic increases 
in antigen-specific CD8+ T cells and antibody responses, repetitive injection of class C 
CpG into mice did not induce splenomegaly, one of the major side effects associated with 
systemic immune activation by CpG. Similar abrogation of systemic toxicity was observed 
in lipid-modified class B and C CpG ODNs, suggesting lipid modification was an effective 
approach to simultaneously improving the efficacy and safety of CpG in vaccines.   
2.4 Conclusions 
Overall, we have confirmed that lipid conjugated CpG ODNs are potent adjuvants 
in vivo. Our findings strongly suggest that in vivo adjuvant properties of CpG do not 
correlate with activities in vitro, highlighting the importance of lymphatic targeting in 
vaccines. Our study extends recent work on CpG as an adjuvant by demonstrating that 
targeting APCs in LN is the key to potentiating adjuvant activities of CpG ODN in vivo.  
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CHAPTER 3 TARGETING SUPPRESSIVE ODN TO LYMPH NODES INHIBITS TLR9-
MEDIATED ACTIVATION OF ADAPTIVE IMMUNITY 
3.1 Introduction  
TLRs are highly conservative transmembrane receptors which are critical factors 
for early detection of foreign pathogens and following initiation of adaptive immune 
responses.45,46 TLRs recognize specific PAMPs associated with microbial pathogens, as 
well as a number of endogenous ligands such as self-protein, lipids, and nucleic acids.45,46 
Other than pathogen sensing and clearance, much research reveals that endogenous 
ligand-mediated signaling through TLR is closely related to the pathogenesis of various 
autoimmune diseases,47-53 such as systemic lupus erythematosus (SLE)50 and 
rheumatoid arthritis (RA)52. In particular, TLRs sensing intracellular nucleic acid, such as 
TLR9, play a pivotal role in the activation of autoimmune pathology.51 For example, under 
certain conditions, TLR9 recognized and sensed self-DNA, leading to the activation of B- 
and T-cells and production of proinflammatory cytokines.53 Such unrestrained infectious 
or self-pathogen DNA-induced immune activation can cause tissue damage, resulting in 
the development of autoimmune diseases such as RA.52,53 Targeting antagonists which 
suppress TLR-mediated immune responses to corresponding TLR receptors may be 
effective in improving the therapeutic efficacy of autoimmune diseases.47,49,54  
It was found that activated immune cells were restrained from secreting pro-
inflammatory and TH-1-promoting cytokines once they were exposed to telomeric DNA 
containing repetitive TTAGGG motifs.55-57 Synthetic ODNs containing repetitive TTAGGG 
motifs which mimic mammalian telomeric sequence can neutralize bacterial DNA-driven 
immune activation.55,58 These suppressive ODNs (Sup-ODNs) can act on dendritic cells 
and macrophages, leading to inhibition of B- and T-cells activation and differentiation.58 
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In several disease models, Sup-ODNs were proved to reduce the level of autoimmune-
mediated stimulation and modulate progression of diseases.58,59 These beneficial effects 
of Sup-ODNs are characterized by inhibition of antigen-specific cellular and humoral 
immune responses as well as downregulation of proinflammatory cytokines.47,58,60 
However, immune suppression and therapeutic benefits were achieved at relatively high 
ODN concentrations.60  Such high-dose treatment can cause serious side effects which 
limit clinical application of Sup-ODNs.61,62 In chronic autoimmune diseases such as RA, 
draining LNs are emerging as therapeutic targets for immune modulation.63 Housing a 
large portion of APCs and lymphocytes, LNs specialize in antigen presentation, defining 
the immunological fates of T- and B-cell responses.11 Since Sup-ODNs act on APCs, we 
hypothesize that approaches targeting Sup-ODNs to APCs in the draining LNs can 
intensify the Sup-ODN-mediated immune suppression, enabling possible dose-sparing 
manner in the treatment of autoimmune diseases.   
We have developed an ‘albumin-hitchhiking’ approach which uniquely targets 
synthetic ODNs to APCs in the LNs.2 In this approach, ODNs were conjugated to an 
albumin-binding diacyl lipid at the 5’-terminal and subsequently accumulated in the 
draining LNs via hitchhiking endogenous albumin after subcutaneous injection.2 The 
efficacy of this approach depends on a structural and molecular design that hijacks traffic 
route of endogenous albumin in the interstitial fluid: following subcutaneous injection, lipo 
ODNs bind avidly to albumin, and transport to draining LNs via lymphatic capillary, and 
accumulate considerably in LN-resident APCs. This approach simultaneously improves 
an immunostimulatory ODN’s adjuvant efficacy and safety by confining the ODN in the 
draining LNs, restraining it from systemic dissemination.2 We hypothesize that the 
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efficacy of immunosuppressive ODNs can be substantially improved by targeting them to 
LNs where a large portion of APCs reside. Here we evaluated inhibitory properties of a 
lipid-modified suppressive ODN in vitro and in vivo. Our results revealed that in vitro, lipid-
modified Sup-ODN encoding repetitive TTAGGG motif enhanced cellular uptake while 
showed similar inhibitory efficacy as unmodified ODN in TLR9-mediated activation. In 
vivo, subcutaneous injection of a low dose of lipo Sup-ODN led to increased accumulation 
in APCs in draining LNs and dramatically suppressed TLR9 agonist-adjuvanted humoral 
and cellular immunity. Collectively, our findings indicated that LN-targeting of Sup-ODN 
via lipid modification may be a promising approach to potentiate immunoinhibitory 
properties of Sup-ODN and thus might be applicable for the control of TLR9-mediated 
immune activation. 
3.2 Materials and methods  
3.2.1 Materials  
All reagents for DNA synthesis were purchased from Glen research (Sterling, VA) 
or Chemgenes (Wilmington, MA) and used following the manufacturer’s instructions. 3’- 
Fluorescein amidite (FAM) labeled controlled pore glass was purchased from Allele 
Biotechnology (San Diego, CA). Fatty acid-free BSA was purchased from Sigma-Aldrich. 
Ovalbumin protein was purchased from Worthington Biochemical Corporation (Lakewood, 
NJ). Murine MHC class I tetramer was obtained from MBL international Corporation 
(Woburn, MA). Antibodies were purchased from eBioscience (San Diego, CA) or BD 
Bioscience (San Jose, CA). All other reagents were from Sigma-Aldrich and used as 
received except where otherwise noted.  
3.2.2 Animals and cells  
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Animals were housed in the USDA-inspected WSU Animal Facility under federal, 
state, local and NIH guidelines for animal care. Female C57BL/6 mice (6-8 weeks) were 
obtained from the Jackson Laboratory. RAW-Blue™ and HEK-Blue™-mTLR9 reporter 
cell lines were purchased from InvivoGen (San Diego, California). Cells were cultured in 
complete medium (DMEM, 10% fetal bovine serum (Greiner Bio-one), 100 U/mL penicillin 
G sodium and 100μg/mL streptomycin (Pen/Strep), DMEM sodium pyruvate (1mM) and 
20μM β-mercaptoethanol (β-ME)). 
3.2.3 Synthesis of diacyl lipid phosphoramidite  
The diacyl lipid phosphoramidite was synthesized as previously described.2 A 
solution of stearoyl chloride (6.789 g, 22.41 mmol) in 1,2-dichloroethane (50 mL) was 
added dropwise to a solution of 1,3-diamino-2-dydroxypropane (1.0 g, 11.10 mmol) in the 
presence of 1,2-dichloroethane (100 mL) and triethylamine (2.896 g, 22.41 mmol). The 
reaction mixture was stirred for 2 h at 25 °C and then heated at 70 °C overnight. The 
reaction mixture was then cooled to 25 °C, filtered, and the solid was sequentially washed 
with CH2Cl2, CH3OH, 5% NaHCO3 and diethyl ether. The product was dried under 
vacuum to give the intermediate product as a white solid (yield: 90%). 1H NMR (300 MHz, 
CDCl3, ppm): δ 6.3 (m, 2H), 3.8 (m, 1H), 3.4-3.2 (m, 4H), 2.2 (t, 4H), 1.6 (m, 4H), 1.3-1.2 
(m, 60H), 0.9 (t, 6H). The intermediate product (5.8g, 9.31mmol) and N, N-
Diisopropylethylamine (DIPEA, 4.2mL, 18.62mmol) was then suspended in anhydrous 
CH2Cl2 (100mL). The mixture was cooled on an ice bath and 2-Cyanoethyl N, N-
diisopropylchlorophosphoramidite (8.6 mL, 0.47 mmol) was added dropwise under dry 
nitrogen. After stirring at 25 °C for 1 h, the solution was heated to 60 °C for 90 min. The 
solution was washed with 5% NaHCO3 and brine, dried over Na2SO4 and concentrated 
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under vacuum. The final product was isolated by precipitation from cold acetone to afford 
4 g (55% yield) lipid phosphoramidite as a white solid. 1H NMR (300 MHz, CDCl3): δ 6.4 
(m, 2H), 3.9 (m, 2H), 3.8 (m, 2H), 3.6 (m, 2H), 3.0-2.9 (m, 2H), 2.6 (t, 2H), 2.2 (m, 4H), 
1.6 (m, 6H), 1.3-1.2 (m, 72H), 0.9 (t, 6H). 31P NMR (CDCl3): 154ppm. 
3.2.4 Synthesis and purification of oligonucleotides  
Both lipid-modified and free Sup-ODN were synthesized on a 1.0 micromole scale 
using an ABI 394 synthesizer. Diacyl lipid phosphoramidite was conjugated as a final 
‘base’ on the 5’ end of oligos. Lipid phosphoramidite was coupled using the DNA 
synthesizer as previously described.2 After the synthesis, ODNs were cleaved from the 
solid support, deprotected, and purified by reverse phase HPLC using a C4 column 
(BioBasic-4, 200 mm x 4.6 mm, Thermo-Scientific). A gradient of 20-60% (buffer B) in 10 
min, was used for the unmodified ODN purification and for lipid-modified ODN, the 
gradient was set at 50-80% (Buffer B) for 10 min and 80-100% for 5 min. Buffer A: 
triethylammonium acetate (TEAA, 0.1 M, pH 7.0), buffer B: Methanol. Lipophilic ODNs 
typically eluted at 12 min while unconjugated oligos eluted at 5 min. Fluorescein label 
ODNs were synthesized using 3’-(6-Fluorescein) tagged controlled pore glass purchased 
from Chemgenes. Lipid-conjugated Sup-ODN  (ODN A151: 5'-ttagggttagggttagggttagggt 
-3’)55 and CpG ODN 1826 (CpG B ODN: 5’-tccatgacgttcctgacgtt-3’)64 were synthesized 
by the above method and characterized by Mass Spec. All ODN sequences were 
modified by phosphothioation to improve stability against nuclease degradation.  
3.2.5 In vitro DC uptake and confocal imaging  
DC2.4 cells were cultured with RPMI-1640 supplemented with 10% FBS and 1% 
P/S, and were incubated with 1 µM FAM-labeled free or lipid-modified Sup-ODN at 37 ℃ 
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for 12 h. After incubation, cells were washed twice with 1 x PBS by centrifuge at 800X g 
for 5 min prior to flow cytometry quantification. To visualize in vitro cellular uptake, DC2.4 
cells were cultured and incubated again under the same experimental conditions and 
were subjected to confocal imaging by Zeiss LSM 510 microscope. 
3.2.6 In vitro TLR reporter cells stimulation  
HEK-Blue™-mTLR9 and RAW-BlueTM cells were purchased from InvivoGen and 
were used to evaluate Sup-ODN’s inhibitory activities in vitro. In a typical procedure, 500 
nM CpG ODN 1826 and 1.5 μM Sup-ODN were added to InvivoGen HEK-Blue™ murine 
TLR9 or RAW-Blue™ mouse macrophage reporter cells, both of which are engineered 
with secreted embryonic alkaline phosphatase (SEAP) reporter gene. After incubating for 
24 h, SEAP levels were quantified by developing supernatants with QuantiBlue™ 
substrate for 1 h and reading absorption at 620nm, following manufacturer’s instructions.  
3.2.7. LNs imaging and cellular uptake  
Groups of C57BL/6 mice (n=4 LNs/group) were injected subcutaneously at the tail 
base with 3.3 nmol of FAM-labeled free or lipid-modified Sup-ODN. After 24 h, animals 
were sacrificed and inguinal and axillary LNs were excised and imaged using In-Vivo 
Xtreme (Bruker) imaging system. LNs were then digested with 1.5 mL freshly prepared 
enzyme mixture comprised of RPMI-1640, 0.8 mg/mL Collagenase/Dispase (Roche 
Diagnostics) and 0.1 mg/mL DNase (Roche Diagnostics). LNs cells were stained with 
antibodies against F4/80 and CD11c versus ODN fluorescence in viable cells. 
Percentages of ODN positive cells in the LNs were determined by flow cytometry. 
3.2.8 In vivo tolerization with lipo ODN A151   
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C57BL/6 mice (6-8 weeks; n=3 per group) were tolerized with PBS, 1.24 nmol of 
free or lipo-Sup ODN on day 0. On day 3, mice were immunized with 3.72 nmol CpG 1862 
ODN plus 10 µg OVA. On day 10, blood was collected from mice and OVA-specific 
immune responses were evaluated. The same mice were tolerized once again as 
previously on day 14 and three days later, a boost injection of 1.24 nmol lipo-G2-CpG 
ODN 1826 2 plus 10 µg OVA was injected into each animal. Blood samples were collected 
on day 24 to analyze the cellular and humoral anti-OVA immune responses. The volume 
of all vaccine injections was 100 µL/mouse. All injections were performed subcutaneously 
at the base of the tail.  
3.2.9 Tetramer staining  
Seven days after challenge, blood samples were collected, and red blood cells 
were lysed by ACK lysing buffer. Cells were then blocked with Fc-blocker (anti-mouse 
CD16/CD32 monoclonal antibody) and stained with SIINFEKL loaded phycoerythrin-
labeled tetramer (Beckman Coulter) and anti-CD8-APC (ebioscience) for 30min at room 
temperature. Cells were washed twice, resuspended in FACS buffer, and analyzed on 
Attune Focus flow cytometer. Analysis typically gated on live CD8+, Tetramer positive 
cells. 
3.2.10 Intracellular cytokine staining  
Peripheral blood was lysed with ACK buffer and washed with PBS twice. Purified 
cells were seeded in 96-well round-bottomed plates and pulsed with 10 μg/mL OVA 
peptide SIINFEKL for 2 h at 37 °C in T-cell media (RPMI-1640, 10% FBS, 50 μM β-
mecaptoethanol, 1% P/S), followed by the addition of brefeldin A for 4 hours. Cells were 
stained with anti-CD8-APC and then fixed using Cytofix following the manufacturer’s 
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instructions. Next, cells were washed and permeabilized. Intracellular staining for anti-
IFN-γ-PE and anti-TNF-α-FITC was performed following the manufacturer’s instructions 
and cells were analyzed by Attune Focus flow cytometer. 
3.2.11 ELISA for OVA-specific IgG  
Mice were bled, and blood samples were collected. Serum anti-OVA IgG levels 
were determined by ELISA: 96-well plates were coated overnight with 10 μg/ml OVA in 
PBS and blocked with 1% BSA in PBS. After incubation of serum samples for 1h at a 
series of dilutions, plates were washed with PBS/1% Tween-20. Goat anti-mouse IgG 
conjugated to Horseradish peroxidase (HRP) was added at 1 μg/ml for 30 min. Plates 
were washed with PBS/1% Tween-20 and ELISA was developed by (3,3’,5,5’-
Tetramethylbenzidine) (TMB, ebioscience). The reaction was stopped by 1 M H2SO4 and 
the absorbance was read at 450 nm and 570 nm using a plate reader. 
3.2.12 Statistical analysis  
All plots represent mean values and error bars represent the standard error of the 
mean (SEM). Comparisons of the mean values of two groups were performed using 
unpaired Student’s t-tests. One-way analysis of variance (ANOVA), followed by a 
Bonferroni post-test, was used to compare >2 groups. *, p<0.05; **, p<0.01; ***, p<0.001; 
ns, not significant unless otherwise indicated. Statistical analysis was performed using 
GraphPad Prism 6 software (San Diego, CA). 
3.3 Results and discussion 
3.3.1 Lipid functionalization of ODN A151 enhances the cellular uptake in vitro 
Synthetic ODN A151 containing TTAGGG motif repeats has been shown to inhibit 
TLR9 signaling and attenuate a variety of inflammatory responses.55 To target ODN A151 
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to the APCs in LNs through the “albumin-hitchhiking” approach, we functionalized A151 
at the 5’-terminal with a diacyl lipid (lipo-A151) as an albumin binding domain. 
Hydrophobic modification of ODNs such as antisense oligos and siRNA has been shown 
to be an effective approach to enhance their cellular uptake.65,66  
 
Figure 3-1. (a) DC 2.4 cells were incubated with 1 μM of free A151 or lipo-A151 
for 12 h at 37 °C. Cells were washed and then subjected to laser scanning confocal 
microscopy imaging for intracellular distribution. Representative confocal images of cells 
treated with A151 (top panels) and lipo-A151 (bottom panels). Scale bar: 20 μm. (b) 
Flow cytometry analysis for quantification of cellular uptake. Data show the mean values 
± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001 by unpaired two-tailed t-
test. 
To test whether lipid modification alters cellular uptake and intracellular distribution 
of ODN A151, we incubated DC2.4 cells with fluorescein-tagged lipo-A151, using 
unmodified ODN A151 as a control. DC2.4 cells treated with lipo-A151 exhibited 
significantly enhanced cellular uptake when compared with unmodified ODN A151 
(Figure 3-1), as showed by flow cytometry and confocal microscopy analysis. Like our 
previous results, lipid-modified ODN preferentially accumulated in intracellular membrane 
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structures.2,66 In vitro, lipid modification promotes quick membrane association and 
following cellular internalization by a mechanism similar to endocytic pathways. In 
contrast, unmodified ODN A151 alone demonstrated less cellular uptake in DC2.4 cells, 
indicating plasma membrane permeability of unmodified ODN A151 was restricted by the 
negatively charged nature of oligonucleotide following exposure to dendritic cells.  
3.3.2 Lipid-modified ODN A151 inhibits CpG-induced immune activation in vitro  
 
Figure 3-2. (a) Free A151 or lipo-A151 (1.5 μM) with or without CpG B ODN (500 
nM) were co-incubated for 24 h in HEK-TLR-9 reporter cells. Cell activation was quantified 
by measuring the SEAP levels in the supernatant. (b) HEK-TLR-9 cells were stimulated 
with 500 nM CpG for 3 h first, after which 1.5 μM of free A151 or lipo-A151 were added 
to the cells. Cell activation was determined. (c and d) HEK-TLR-9 cells were incubated 
with A151, or lipo-A151 for 12 h, after which cells were washed (c), or without a wash (d) 
before CpG ODN (500 nM) was added for the TLR-9 stimulation. (e and f) A151 and lipo-
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A151 were co-incubated with imiquimod (TLR-7 agonist) (e) or lipopolysaccharide (LPS) 
(TLR-4 agonist) (f) for 24 h in Raw-Blue reporter cells. Data show the mean values ± SEM. 
*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by one-way 
ANOVA with Bonferroni post-test. 
Modification on immunostimulatory ODNs often influences their biological 
functions.2,67 To test whether lipid modification on ODN A151 compromises its inhibitory 
activity, the immune suppressive properties of both lipo-A151 and unmodified A151 were 
first evaluated in murine TLR9 (mTLR9) reporter cells. HEK-Blue cells transfected with 
murine TLR9 and an NF-κB-inducible SEAP (secreted embryonic alkaline phosphatase) 
reporter gene were incubated with lipo-A151 or free A151 in the presence of CpG ODN 
and the activation of NF-κB was quantified by measuring the SEAP concentrations in the 
supernatant. TLR9 reporter cells were activated when stimulated with a class B CpG ODN 
(CpG ODN 1826, 500 nM) which specifically bound to mTLR9 (Figure 3-2 (a)). CpG-
dependent TLR9 stimulation was inhibited by up to 75% following incubation with free 
A151 (1.5μM). Residual TLR9 activation was retained in cells treated with free A151, 
showing a small but statistically significant increase in SEAP production as compared 
with no treatment group (Figure 3-2 (a)). However, the addition of same concentration of 
lipo-A151 completely inhibited the CpG ODN induced TLR9 activation in HEK cells 
(Figure 3-2 (a)), lowering the SEAP production to the basal level that was statistically 
indistinguishable from control levels (Figure 3-2 (a)).  The successful inhibition of CpG-
induced TLR9 activation required treatment of TLR9 cells with suppressive ODN before 
or during the CpG stimulation, as both lipo-A151 and free A151 were unable to reduce 
the SEAP production when mTLR9 cells were stimulated with CpG prior to addition of 
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suppressive ODN (Figure 3-2 (b)). However, when mTLR9 cells were treated with 
suppressive ODN for 3 hours, washed, and then stimulated with CpG ODN, both free 
A151 and lipo-A151 were partially effective in the suppression of TLR9 activation (Figure 
3-2 (c)). In this case, statistically significant inhibition persisted for lipo-A151, showing 
retention of 50% of its inhibitory capacity compared to unmodified A151 (Figure 3-2 (c-
d)). These findings suggest that instead of compromising the suppressive properties, 
lipid-modification on A151 enhances the inhibitory efficacy of TLR9 stimulation. To test 
whether lipo-A151 can act broadly to suppress immune activation elicited by other TLR 
stimulants,68,69 Raw-Blue cells were used to replace mTLR9 cells as reporter cells in the 
above experiments. Raw-Blue cells are stably transfected with SEAP gene and NF-κB 
inducible by many pattern-recognition receptors, including Toll-like receptors (except 
TLR5) and NOD-like (nucleotide-binding oligomerization domain-like) receptors. In 
contrast to inhibition of NF-κB activation by a TLR9 agonist, both lipo-A151 and 
unmodified ODN A151 showed little suppressive effect on Raw-Blue cells stimulated by 
imiquimod (TLR7 agonist) and LPS (lipopolysaccharide, TLR4 agonist) (Figure 3-2 (e-f)), 
respectively, suggesting in these reporter cells, ODN A151 was a TLR9-specific inhibitor. 
3.3.3 Lipid-modified ODN A151 accumulates in draining LNs in vivo  
Our previous study showed that lipid-modified ODNs accumulated in the LNs 
following subcutaneous injection by binding and trafficking with endogenous albumin.2 To 
test whether lipid modification results in efficient trafficking of ODN A151 to draining LNs, 
we assessed LN accumulation of ODN A151 following subcutaneous injection. C56BL/6 
mice were injected subcutaneously with 3.3nmol FAM-labeled free A151 or lipo-A151 at 
the tail base and 24 h later, inguinal and axillary LNs were isolated and imaged. 
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Consistent with our previous findings, lipid-modified A151 exhibited 10- and 18-fold 
increases in inguinal and axillary nodes than unmodified A151, respectively (Figure 3-3 
(a-b)). To identify the cells in the LNs that internalized ODN A151, the LNs were digested 
and stained with antibodies against F4/80 and CD11c. By flow cytometry, cellular uptake 
of lipo-A151 in the draining LNs was highest in APCs, with the majority of lipo-A151 
accumulated in CD11c+ DCs and F4/80+ macrophages (Figure 3-3 (c-d)). These cells 
were key APCs that specialized in antigen presentation and immune activation. In accord 
with the imaging analysis, lipo-A151 showed considerably more uptake in both DCs and 
macrophages than free A151. Together, these results confirmed that in vivo, lipid 
functionalized A151 efficiently accumulated in the APCs in the draining LNs.  
 
Figure 3-3. Mice (n = 4 LNs/group) were injected s.c. at the tail base with 3.3 nmol 
FAM-labeled A151 or lipo-A151. Inguinal LNs (proximal nodes) and axillary LNs (distal 
nodes) were isolated 24 h post injection and were imaged (a) and quantified (b) by using 
In-Vivo Xtreme (Bruker) imaging system. (c and d) LNs were digested and LNs cells were 
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stained with antibodies against F4/80, CD11c. Percentages of A151 ODN positive cells 
in inguinal nodes (c) and axillary nodes (d) were determined by flow cytometry at 24 h. 
Data show the mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 
0.0001 by unpaired two-tailed t-test.  
3.3.4 Lipid-modified ODN A151 inhibits CpG ODN-induced antigen-specific 
cellular and humoral responses in vivo  
To determine whether LNs targeting suppressive ODN A151 can suppress the 
CpG-induced immune responses in vivo, the inhibitory effects of lipo-A151 versus 
unmodified A151 on vaccine-induced T- and B-cell responses were evaluated. Naïve 
C57BL/6 mice were tolerized with a low dose (1.24nmol) of lipo-A151 or unmodified A151, 
by subcutaneous injection at the tail base. Three days later, all the animals were 
challenged with a large dose of CpG (3.72nmol) plus 10μg of ovalbumin (OVA). OVA-
specific immune responses were determined in the blood on day 10 (Figure 3-4 (a)). 
ODN A151 at this dosage had little impact on OVA-specific CD8+ T cells, as similar 
frequencies of OVA tetramer+ CD8+ T cells were seen in mice tolerized with unmodified 
A151 and PBS (Figure 3-4 (b-c)). In contrast, lipo-A151 treatment notably reduced the 
frequency of antigen-specific CD8+ T cells in the blood (Figure 3-4 (b-c)). An identical 
tolerization injection was administered on day 14 and three days later, mice were 
challenged with 1.24nmol LN-targeting CpG (lipo CpG) mixed with 10μg OVA. As shown 
in Figure 3-4 (b) and (d), CD8+ T cell responses after boost were relatively potent in mice 
tolerized with PBS or unmodified A151, characterized by 17.5% and 14% tetramer-
positive CD8+ T cells in the blood, respectively. However, in mice tolerized with lipo-A151, 
less than 5% of CD8+ T cells in blood were OVA-specific. To our knowledge, this is the 
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first example where the priming of CD8+ T cells is suppressed to such a low level without 
using a global immunosuppressant. Interestingly, at this low (1.24nmol) dose used, both 
A151 and lipo-A151 significantly reduced TH-1-biased CD4+ T cells capable of secreting 
IFN-γ after antigen re-stimulation (Figure 3-4 (e)). Additionally, we measured the levels 
of OVA-specific IgG in the sera of immunized mice to assess the ability of lipo-A151 to 
mediate humoral immunity. Sera from immunized mice were collected on day 27 following 
the initial treatment. ELISA measurements of serum titers of OVA-specific IgG showed a 
significantly lower level of anti-OVA IgG in mice tolerized with lipo-A151 but not 
unmodified A151 (Figure 3-4 (f)). Together, these results suggested LN-targeting 
suppressive ODN A151 dramatically improved immune suppressive activities that 
modulated both the CD8+ T cell- and B cell-mediated immunity. 
 
Figure 3-4. (a) Tolerizing model displays experimental protocol. C57Bl/6 mice 
(n = 3/group) were tolerized with PBS, 1.24 nmol of A151, or lipo-A151 on day 0 and day 
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14. Mice were challenged with 3.72 nmol CpG ODN plus 10 μg OVA on day 3 and 1.24 
nmol lipo-CpG ODN plus 10 μg OVA on day 17. One week after each challenge (day 10 
and day 24), blood samples were collected and antigen-specific CD8+ T-cell responses 
in peripheral blood were evaluated by SIINFEKL tetramer assay. (b) Representative flow 
cytometric plots of H-2Kb/SIINFEKL tetramer staining of CD8+ cells post-prime (upper 
panels) and post-boost (lower panels). (c and d) Quantification of SIINFEKL tetramer-
positive CD8+ cells in the blood after CpG and OVA antigen prime (c) and boost (d). (e) 
Stimulation of white blood cells ex vivo for 6 h in the presence of OVA showed a reduced 
response in CD4+ T cells after tolerization using A151 or lipo-A151 compared with PBS. 
IFN-γ-secreting CD4+ T cells frequencies were determined by intracellular cytokine 
staining. (f) On day 24, serum samples were collected and assayed by ELISA for anti-
OVA IgG production. Data show the mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p 
< 0.001; ****, p < 0.0001; ns, not significant by one-way ANOVA with Bonferroni post-test. 
Enhancing activation of innate immunity and thereby potentiating adaptive immune 
responses has long been considered in a clinic in the treatment of cancer, allergy, and 
infections.45,46 In parallel with the discovery of CpG ODN in activating TLR9 and inducing 
potent antigen-specific immunity, it was found activation of innate immunity through TLR, 
such as TLR9, could lead to deleterious immune responses that resulted in the 
destruction of self-tissues.47-53 This has sparked the search for specific inhibitors which 
could inhibit CpG-mediated activation.47-53 Studies have revealed several structurally 
distinct ODNs can differentially modulate TLR9-mediated immune stimulation and 
suppress the biological activity of TLR9 ligation.55,58,60,68 In particular, ODNs containing 
immunosuppressive motif TTAGGG were recognized for their ability to attenuate 
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inflammatory responses in vivo by blocking TLR9 signal pathways.58,68 Administration of 
A151 (a representative suppressive ODN with TTAGGG motif) has been shown to inhibit 
dendritic cell activation, suppress TH-1 differentiation and support the induction of 
regulatory T cells, prevent STAT1 and STAT4 phosphorylation, block cytosolic nucleic 
acid sensing pathways.58 However, systemic administration of phosphorothioate ODN is 
known to induce side effects including platelet activation, which has limited the clinic 
translation of suppressive ODN in humans.61,62  
Emerging evidence supports the contribution of LNs in the generation and 
perpetuation of autoimmunity resulted from chronic inflammation.11,63 During the 
progression of autoimmune diseases such as RA, antigens and inflammatory signals (e.g., 
DNA) resulted from the immune destruction drain into the LNs and aggravate the 
pathogenic inflammation.63 Thus, approaches that target and modulate the immune cell 
cross-talk and reciprocal interactions within the LNs microenvironment hold great promise 
for the treatment of autoimmune inflammation.   
We present here the results of our attempt to design and implement an ‘albumin-
hitchhiking’ approach to locally deliver an immune suppressive ODN to draining LNs to 
suppress the TLR9-activation-induced adaptive immune responses. We previously 
developed a diacyl lipid-ODN conjugation which uniquely targeted ODNs to APCs in the 
LNs via an albumin-mediated transportation.2 Albumin-binding domain increases the 
hydrodynamic size of ODN and prevents it from diffusing into blood circulation, re-
targeting it to the lymphatics where a large portion of APCs reside. In addition to LNs 
targeting, lipo-ODN exhibited high affinity toward membrane and accumulated in the 
endosome.2,66 We assessed the in vitro and in vivo properties of diacyl lipid-modified ODN 
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A151. In vitro, lipo-A151 significantly enhanced the cellular uptake compared with 
unmodified A151. Our data are consistent with previous observation where hydrophobic 
conjugation on siRNA resulted in the enhancement of cellular uptake.65 We observed that 
although co-presence of lipo-A151 and CpG was most effective at inhibiting TLR9 
activation in HEK-TLR9 cells, lipo-A151 still resulted in partial inhibition when it was 
incubated with cells for 3 hours prior to CpG stimulation, showing a significantly better 
suppression than unmodified A151. Our results suggest that in vitro, lipid modification on 
A151 not only keeps intact its suppressive properties toward TLR9 stimulation but also 
leads to prolonged suppression when CpG ODN was added later.  
In vivo, diacyl lipid-modified A151 accumulated in the draining LNs following 
subcutaneous injection. The LNs enrichment was consistent with our previous 
observations where lipid-modified ODNs bound endogenous albumin and transported to 
the LNs.2 In contrast, unmodified ODN quickly diffused into blood circulation due to its 
small molecular size, and exhibited minimal LNs accumulation.2,70 Flow cytometry 
analysis of cells in the LNs revealed that CD11c+ dendritic cells and F4/80+ macrophages 
were the major cells responsible for the uptake of lipo-A151. These cells are key APCs in 
the LNs that actively bind and internalize macromolecules such as albumin.71 
Using the well-studied ovalbumin as a model antigen, we also assessed the ability 
of LNs targeting lipo-A151 to suppress the OVA-specific immunity in vivo. 
Subcutaneously injected OVA combined with TLR9 ligand CpG ODN induced potent 
CD8+ T cell and humoral responses, mimicking the inflammatory responses of 
autoimmune diseases. Injection of LN-targeting lipo-A151, but not unmodified A151, 
effectively suppressed OVA-specific CD8+ T cell and B cell immune responses, 
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demonstrating our LNs targeting strategy was superior in the immune inhibition. In a real 
situation, autoimmune diseases can be triggered by multiple TLR stimulations.47 In our 
experiments, the immune suppression by lipo-A151 appeared to be TLR9 specific, as no 
suppressive effect was observed for lipo-A151 when Raw-Blue cells were stimulated with 
TLR7 (imiquimod) or TLR4 (lipopolysaccharide, LPS) agonists. However, broad-spectrum 
ODN-based antagonists have been recently demonstrated. For example, IMO-3100 72 
and IMO-8400 73 were reported to act as antagonists against multiple TLRs, including 
TLR7, TLR8, and TLR9. Thus, it is possible to extend our approach to other endosomal 
TLR antagonists with broad immunosuppressive capacity. Although clinical safety data of 
phosphorothioate ODN were well documented, long-term toxicity effects are lacking. For 
example, a recent study has shown the development of antibodies against 
phosphorothioate ODN in patients.74 As our approach targets lipo-A151 to the LNs, it is 
possible that there may exist a potent anti-lipo-A151 antibody response. 
We leveraged albumin to target LNs, which accommodates a wide variety of 
immune cells including APCs, T cells and B cells. Unlike nanoparticles that require 
sophisticated encapsulation design or modification, this delivery system exhibits a natural, 
simple and efficient way to target LNs and modulate the immune response. Our results 
may pave the way to amplify the induction of immunosuppression in the immune 
modulation that would target autoimmune conditions. 
3.4 Conclusions 
In summary, the data presented in this study suggest that the targeted delivery of 
immunosuppressive ODN to LNs by “albumin-hitchhiking” improves its inhibitory activities 
in vitro and in vivo. This finding emphasizes the potential of targeting immunomodulators 
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to the LNs in the treatment of autoimmune diseases. Further work is required to assess 
the effectiveness of suppressing human TLR-driven inflammation by lipid-modified ODN.  
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CHAPTER 4 STRUCTURE-DEPENDENT STABILITY OF LIPID-BASED POLYMER 
AMPHIPHILES INSERTED ON ERYTHROCYTES  
4.1 Introduction  
Cell-based therapy has attracted much research attention and is a rapidly 
expanding field in treating many diseases, including cancer, neurological diseases, and 
autoimmune disorders.75-77 As the molecular landscape of the plasma membranes 
dominates interactions of cells with the surrounding environment, therapeutic cells are 
often engineered to regulate cell functions such as cell survival, adhesion, migration, 
targeting, cell-cell interactions, or to enable targeted drug transport.78-83 Cell surface 
engineering utilizes engineering, chemistry, and biology techniques to enable 
modification of cell surface molecules with targeting ligands, biological functionalities, 
nanoparticles, or synthetic drugs. However, the complex and dynamic nature of cell 
surface sets a significant barrier for efficient modification without physically compromising 
fundamental cell functions such as viability, adhesion, migration, and immune recognition. 
To date, many approaches to engineering cell surface have been developed. For 
example, genetic engineering is a versatile and robust methodology to express or 
suppress specific cell surface molecules.84 However, technical difficulties and safety 
concerns such as limitation of cell types and restriction of introducible therapeutic 
materials have confined its wide applications in the clinical setting. In parallel, another 
approach that involves covalent chemical modification of cells can be utilized to conjugate 
a broad range of functional molecules to the cell surface. This approach mainly engineers 
functional groups including amines, thiols, and carboxyls present in proteins, 
carbohydrates, or lipids on the cell surface.85 A major disadvantage of covalent 
functionalization is a possible abrogation of biological functions of native proteins. Cell 
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surface functionalization by lipid-based amphiphiles which are capable of spontaneously 
and exogenously inserting into the plasma membranes is a great alternative approach 
which can circumvent those limitations. To facilitate spontaneous membrane insertion, 
these amphiphiles are designed with a functional moiety of interest, which is conjugated 
to a suitable hydrophobic anchor (e.g., lipid or steroid) via a solubility-enhancing 
polymeric spacer (e.g., PEG). This approach is simple, allowing rapid and uniform surface 
functionalization of a wide variety of molecules without compromising the cell viability and 
functions. We chose to utilize erythrocytes as mature RBCs feature long circulation time 
(up to 120 days) and reduced endocytosis. Although these lipid-based amphiphiles 
appear to be stably anchored on the cell surface under cell culture conditions, their 
stability under mechanical stress (e.g., in the blood flow) in the presence of blood remains 
uncharacterized. Since many cells used in cell-based therapies need to enter the blood 
circulation, it is important to evaluate the retention of membrane-anchored amphiphiles in 
vivo. In this study, we analyzed and compared the effect of the molecular structure of 
lipid-based amphiphiles on their kinetic stability on the erythrocyte surface under static 
condition and mechanical stress. Our results revealed that longer diacyl lipid chain offered 
amphiphiles more stable retention kinetics on RBCs, while shorter PEG spacers were 
preferred for greatly extended circulation half-life on RBCs in vivo. Besides, we revealed 
that fluid shear stress and plasma serum promoted the release of amphiphiles anchored 
on RBCs. More importantly, cationic lipids conjugated amphiphile exhibited dramatically 
improved the retention kinetics on RBCs in vivo and led to a 40-fold increase in circulation 
half-life compared to the anionic lipid-modified one. These results emphasized the 
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significance of structural design in the retention kinetics of membrane-anchored 
amphiphiles. 
4.2 Materials and methods 
4.2.1 Materials  
DMT hexaethyloxy glycol phosphoramidite and all reagents used on ABS 394 DNA 
synthesizer were purchased from Glen research or Chemgenes and used following 
manufacturer’s instructions. Vybrant DiD Cell-Labeling Solution was purchased from 
Thermo Scientific. 3’-FAM resin was purchased from Allele Biotechnology. DSPE-PEG-
NH2 was bought from Laysan Bio Inc. NHS-FITC and NHS-PEG-FITC 2000 were 
purchased from Nanocs Inc. All other reagents were purchased from Sigma-Aldrich 
except where otherwise noted.  
4.2.2 Synthesis of diacyl lipid phosphoramidite  
The C18 diacyl lipid phosphoramidite was synthesized as previously described.2 A 
solution of stearoyl chloride (6.789 g, 22.41 mmol) in 1,2-dichloroethane (50 mL) was 
added dropwise to a solution of 1,3-diamino-2-dydroxypropane (1.0 g, 11.10 mmol) in the 
presence of 1,2-dichloroethane (100 mL) and triethylamine (2.896 g, 22.41 mmol). The 
reaction mixture was stirred for 2 h at 25 °C and then heated at 70 °C overnight. The 
reaction mixture was then cooled to 25 °C, filtered, and the solid was sequentially washed 
with CH2Cl2, CH3OH, 5% NaHCO3, and diethyl ether. The product was dried under 
vacuum to give the intermediate product as a white solid (yield: 90%). 1H NMR (300 MHz, 
CDCl3, ppm): δ 6.3 (m, 2H), 3.8 (m, 1H), 3.4−3.2 (m, 4H), 2.2 (t, 4H), 1.6 (m, 4H), 1.3−1.2 
(m, 60H), 0.9 (t, 6H). The intermediate product (5.8 g, 9.31 mmol) and N, N-
diisopropylethylamine (DIPEA, 4.2 mL, 18.62 mmol) was then suspended in anhydrous 
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CH2Cl2 (100 mL). The mixture was cooled on an ice bath and 2-cyanoethyl N, N- 
diisopropylchlorophosphoramidite (8.6 mL, 0.47 mmol) was added dropwise under dry 
nitrogen. After stirring at 25 °C for 1 h, the solution was heated to 60 °C for 90 min. The 
solution was washed with 5% NaHCO3 and brine, dried over Na2SO4, and concentrated 
under vacuum. The final product was isolated by precipitation from cold acetone to afford 
4 g (55% yield) lipid phosphoramidite as a white solid. 1H NMR (300 MHz, CDCl3): δ 6.4 
(m, 2H), 3.9 (m, 2H), 3.8 (m, 2H), 3.6 (m, 2H), 3.0−2.9 (m, 2H), 2.6 (t, 2H), 2.2 (m, 4H), 
1.6 (m, 6H), 1.3− 1.2 (m, 72H), 0.9 (t, 6H). 31P NMR (CDCl3): 154 ppm. The C12 diacyl 
lipid phosphoramidite was synthesized following the same procedures above except that 
the final product was purified by silica gel column chromatography. 
4.2.3 Synthesis and purification of fluorescein-labeled lipo-(EG)n  
All anionic lipo-(EG)n were synthesized using an ABI 394 synthesizer on a 1.0 
micromole scale. DMT-hexaethyloxy glycol phosphoramidites were conjugated as a ‘base’ 
initiated from 3’-(6-Fluorescein) labeled controlled pore glass. All lipophilic 
phosphoramidites were conjugated as a final ‘base’ on the 5’ end of the sequence in the 
DNA synthesizer. After synthesis, lipo-(EG)n were cleaved from the solid support and 
deprotected, purified by HPLC using a reverse phase C4 column (BioBasic-4, 200mm X 
4.6mm, Thermo Scientific), 100mM triethylamine-acetic acid buffer (TEAA, pH7.5)-
Methanol (0-15min, 50-100%) as an eluent. Fluorescein-labeled lipo-(EG)n typically 
eluted at 14 min detected by the wavelength of 480nm. All other lipo-PEG amphiphiles 
were purified by HPLC using the same eluting method.  
4.2.4 Synthesis of cationic lipid  
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To a 50 mL round-bottom flask, 0.6 g (3.744 mmol) of NBoc-ethylenediamine and 
3.744 g (11.232 mmol) of octadecyl bromide was taken in ethyl acetate (12 mL) and 
refluxed in the presence of anhydrous potassium carbonate (2.069 g; 14.976 mmol) for 
24h. After completion, the mixture was diluted to 100 mL ethyl acetate, and washed with 
water (2 X 100 mL), dried over anhydrous magnesium sulfate and filtered. Ethyl acetate 
was removed by rotary evaporation. The residue was purified by silica gel column 
chromatography to afford 0.5 g intermediate product (10% ethyl acetate in hexane, v/v, 
as the eluent).MS(LC-MS) calculated: m/z 664.68; found: 665.67. To a 25 mL round-
bottom flask, the intermediate product and 0.3 g methyl iodide was taken in 10mL acetone 
and refluxed for 24 h. The reaction mixture was concentrated under reduced pressure 
and the residue was washed twice with 50 mL hexane by centrifuge for 10 min at 
maximum speed to yield 0.3 g white powder. MS(LC-MS) calculated: m/z 679.71; found: 
679.55.  
 
Scheme of synthesis of cationic lipid 
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The white powder obtained (0.3 g, 0.44 mmol) was dissolved in 6 mL of anhydrous 
dichloromethane (DCM) and 2 mL trifluoroacetic acid (TFA) was added. The reaction 
mixture was stirred at room temperature for 24 h. After completion, the reaction mixture 
was mostly concentrated by rotary evaporator and vacuumed by oil pump overnight 
without further purification. Afterward, 10 mL NaOH (1N) and 10 mL dichloromethane 
were added the unpurified product and the biphasic mixture was stirred at room 
temperature (RT) for 2 h. The organic layer was washed with water (20 mL x 3), dried 
over magnesium sulfate and filtered. The solvent in the filtrate was completely removed 
by rotary evaporator and then vacuumed oil pump overnight to afford 0.15 g final product. 
MS(LC-MS) calculated: m/z 579.66; found: 579.56. 
4.2.5 Synthesis and purification of fluorescein-labeled cationic lipo PEG.  
6 mg (10.51 μmol) of cationic lipid and 13 mg (4.2 μmol) of NHS-PEG-FITC 2000 
was dissolved in 1mL dimethylformamide (DMF) and the reaction mixture was stirred at 
RT overnight in the presence of 1μL of triethylamine (TEA). After completion, the mixture 
was purified by HPLC as previously described. 
4.2.6 Synthesis of fluorescein-labeled DSPE-PEG-2000  
5.2 mg of DSPE-PEG-NH2 2000 and 1.7 mg of NHS-FITC was dissolved in 1mL 
dimethylformamide (DMF) and the reaction mixture was stirred at RT overnight in the 
presence of 1 μL of triethylamine (TEA). After completion, the mixture was purified by 
HPLC. 
4.2.7 Insertion of amphiphilic cargos on RBC ex vivo  
Fresh blood was collected from Balb/c mice.10 μL whole blood was washed twice 
with PBS(1x) and resuspended in 100 μL PBS. Then fluorescein labeled lipo PEG was 
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added into RBC suspension at a final concentration of 5 μM and incubated at 37 °C for 1 
h. Afterward, samples were washed with PBS (1 X) twice to remove excessive unbound 
lipo PEG, and the residue was further incubated with whole blood, plasma serum (original 
concentration in whole blood) or pure RBC suspension (original cell density in whole 
blood). At designated time points, a small aliquot of the mixture was washed and then 
assayed by flow cytometry.  
4.2.8 In vivo kinetics study  
RBC from 100 μL whole blood was treated with fluorescein-labeled lipo PEG as 
described previously and resuspended in 150 μL PBS (1 X). If necessary, RBC was 
further treated with DiD dye after amphiphilic cargo insertion. A Balb/c mouse was i.v. 
injected with 150μL treated RBC suspension at the tail and was bled at the tail tip for 
flow cytometry analysis at the designated time point.  
4.2.9 Exertion of shear stress on RBCs  
RBC was treated as previously described. 5 µL treated RBC was mixed with 100 
µL whole blood or RBC suspension or plasm serum (diluted to physiological concentration 
with 1 X PBS). After mixing, samples were then loaded onto ARES rheometer plate and 
sheared at 3000 1/s for 15 min at room temperature. When shearing was completed, 1 
µL fresh sample was collected immediately for flow cytometry analysis. Besides shear 
stress exerted by rheometer, a syringe pump with a flow rate of 0.30 mL/min was set to 
shear samples mixed with whole blood for 12 min. 
4.2.10 Hemolysis of RBC  
The freshly collected blood was washed with PBS (1X) and then was resuspended 
in PBS (1X) with 50 times dilution. Each well 200 µL of RBCs suspension was incubated 
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at 37 °C for 1 h with 5 µM amphiphilic cargoes, 1% Triton-X 100 (v/v) or without treatment 
in a round-bottomed 96-well plate. For each group, samples were loaded in quadruplicate. 
After incubation, the plate was centrifuged for 5 min at 500 x g to pellet intact RBCs. 100 
µL of supernatant from each well was transferred into a flat-bottomed 96-well plate. The 
absorbance of hemoglobin was measured by UV-vis plate reader at 540 nm. After 
background subtraction, the hemolysis percentage of each group was normalized to 
positive control Triton-X 100 group which represented 100% hemolysis.   
4.3 Results and discussion 
4.3.1 The effect of the length of lipid and PEG spacer on membrane retention time 
To mimic the complex biological environment after injection, RBCs (isolated from 
10 µL mouse whole blood) were incubated with 5 µM of different dye-labeled amphiphiles 
(Figure 4-1 (a)) in PBS buffer, washed, and mixed with 100 µL whole blood at 37 °C for 
1 h. To reduce the competitive binding from serum proteins, RBCs were separated from 
serum and resuspended in PBS buffer (1 X). The retention of amphiphiles on the RBC 
surface was quantified by flow cytometry over time. Like previous studies,2 amphiphilic 
polymers with short lipid tail (12 carbons) rapidly dissociated from RBC surface when 
mixed with whole blood. 15 minutes after incubation, no populations with fluorescent 
signal was detectable in both C12-EG6 and C12-EG48 treated RBCs, suggesting a rapid 
and complete release of short lipid tail (C12-PEG) from RBC surface when mixed with 
blood (Figure 4-1 (b-c)). By contrast, the frequency of FITC-positive cells remained 
constant in RBCs loaded with long lipid (C18)-conjugated amphiphiles for more than 3 
hours (Figure 4-1 (b-c)). These results suggested that sufficient hydrophobicity was 
required to firmly anchor the payload on the RBC surface in the presence of blood. 
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Interestingly, we also observed the amphiphiles with a long PEG block were released at 
a faster rate than those with a shorter PEG spacer, as shown in Figure 4-1 (d). 
Additionally, we noticed that RBCs, but not plasma serum, played a vital role in burst 
release of amphiphiles at the instance when amphiphiles-loaded RBCs were mixed with 
whole blood (Figure 4-1 (e-f)). It is worth pointing out that neither PEGs modified with 
C18 lipids caused hemolysis to RBCs (Figure 4-1 (g)). The reductions in fluorescence 
intensity were caused by the release of amphiphiles from cells into the culture medium. 
This could be due to the increased interaction between high molecular weight PEG with 
serum protein. 
 
Figure 4-1. (a) Structures of C12 and C18 lipid-modified PEG amphiphiles. (b) 
Representative flow cytometry plots of FAM-labeled lipo PEG-loaded RBCs. (c) The 
frequency of RBC inserted by C12 or C18 lipid conjugated (EG)6 or (EG)48 over 200 min. 
(d) The relative release percentage of C18 lipid conjugated (EG)6 or (EG)48 over 200 min. 
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(e) The relative burst release percentage of C18 lipid conjugated (EG)6 or (EG)48 at 
different time points over 30 min. The release of FAM lipo-(EG)n on RBC before mixing 
with untreated RBC suspension was set to 0%. (f) Mean Fluorescence Intensity of FAM-
labeled lipo-(EG)n on RBC before and after mixing with plasm serum diluent (1X). (g) The 
viability of RBCs treated with lipo PEG amphiphiles. Each specimen was assayed with 
three replicates. Error bars represent the SEM.  
4.3.2 The effect of shear stress on the stability of membrane-anchored 
amphiphiles 
Having demonstrated the structure-based stability of amphiphiles under static 
conditions, we set out to evaluate the mechanical impact to the amphiphiles loaded on 
the RBCs surface. Unlike static cell culture conditions, cells are exposed to various levels 
of mechanical stresses in the circulatory system under physiological conditions. Thus, the 
stability of membrane-anchored amphiphiles under mechanical stress is expected to be 
different when compared to that under static conditions. 
 
Figure 4-2.  (a) Representative flow cytometry plots of C18 lipo (EG)6- and lipo 
(EG)48-inserted RBCs treated with or without plate shearing stress. The percentage of 
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relative fluorescence decrease in C18 lipo (EG)6- and lipo (EG)48-inserted RBC after 
plating shearing (b), or after syringe pumping (c). Each specimen was assayed with three 
replicates. Error bars represent the SEM. Data show the mean values ± SEM. *, p < 0.05; 
**, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by using unpaired Student’s 
t-tests. 
To test this hypothesis, lipid-conjugated PEGs loaded RBCs were subjected to in 
vitro shear conditions. A stress-controlled commercial rheometer was used to administer 
shear stress to amphiphiles-loaded RBCs. As shown in Figure 4-2 (a-b), under 
mechanical stress, the amphiphiles were released significantly faster than under static 
conditions. After being sheared at a rate of 3000 1/s for 15 min, 7.5% C18-(EG)6 and 29.2% 
C18-(EG)48 were released from RBC surfaces, as compared to 4.3% and 6.9% under 
static conditions. In both dynamic and static situations, long PEG-linked amphiphile was 
released at a higher rate than short PEG conjugated one, suggesting the length of PEG 
spacer was an important factor that controlled the membrane stability after insertion. In 
our experiment, amphiphiles loaded RBCs were mixed with freshly isolated whole blood. 
It was possible that the release was caused by competitive association from unlabeled 
RBCs or the serum proteins. To investigate the role of different blood components in the 
observed release, amphiphiles-loaded RBCs were sheared after mixing with separated 
erythrocytes or serum respectively. As shown in Figure 4-2 (b), it appeared that serum 
was the dominant factor responsible for the amphiphile release. To simulate the 
physiological conditions of blood flow-induced shear stress, amphiphiles-loaded RBCs 
were mixed with whole blood and pumped through a capillary tube (0.1 mm in diameter). 
The pressure and flow rate were controlled by regulating the pump speed to 0.30 mL/min 
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for 12 min. Similar release profiles were obtained by this extracorporeal model (Figure 4-
2 (c)). These two in vitro models demonstrated the mechanical stress accelerated the 
release of lipid-based amphiphiles on RBC surface. 
4.3.3 In vivo stability of membrane-anchored amphiphiles  
 
Figure 4-3. (a) Representative flow cytometry plots of in vivo kinetics of FAM-
tagged lipo-(EG)6, lipo (EG)48 and DSPE-PEG 2000 loaded RBC, (b) The relative 
frequency decrease of RBCs loaded with FAM-tagged C18 lipo (EG)6, lipo (EG)48 and 
DSPE-PEG 2000 at different time points over 24h, (c) The relative release percentage of 
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C18 lipo (EG)6, lipo (EG)48 and DSPE-PEG 2000 at different time points over 24h. Each 
specimen was assayed with three replicates. Error bars represent the SEM. 
To investigate in vivo stability of amphiphiles loaded on RBCs, RBCs loaded with 
C18 lipid-conjugated amphiphiles were injected intravenously into mice. Blood samples 
were analyzed at different time points. As shown in Figure 4-3, the release rate of 
amphiphiles constructed with long PEG (C18-(EG)48) was significantly faster when 
compared to that at static cultures. Under static conditions, the frequencies of RBCs 
treated with C18 lipid-modified amphiphiles remained constant over 3 hours’ incubation. 
However, 1 hour after injection, the fluorescence positive RBCs, carrying amphiphiles 
linked with long PEG, dropped to an undetectable level. Surprisingly, the release rate of 
amphiphiles conjugated with short PEG in vivo was comparable to that under static cell 
culture conditions, suggesting that in vivo conditions affected longer PEG more 
profoundly than short PEG in terms of the stability. 
4.3.4 Cationic lipid conjugation on amphiphiles prolongs membrane retention in 
vivo. 
The fast dissociation rate of long PEG-conjugated amphiphiles from the RBCs 
surface in vivo raises the question of how to improve it. Fluorescent lipophilic dyes (e.g., 
long-chain dicarbocyanine) are widely used to label the plasma membrane. For long-term 
dye retention on cells, these dyes share some common design characteristics such as 
fluorophore directly conjugated to long aliphatic tail to ensure strong hydrophobic 
interactions with surrounding lipids. However, due to the relatively short hydrophilic 
fluorescent head, in salt-containing buffers, these dyes rapidly form micelles or aggregate 
and require special diluent for optimal staining. 
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Figure 4-4. (a) Structure of fluorescein-tagged cationic DSPE-PEG-2000, (b) The 
fluorescence release profiles of C18 lipo (EG)6, lipo (EG)48 and cationic DSPE-PEG-2000 
under static conditions, (c) Representative flow cytometry plots of in vivo kinetics of 
cationic amphiphile-loaded RBCs, (d) The relative frequency decrease of RBCs loaded 
with cationic amphiphiles at different time points over 72 h, (e) The relative release 
percentage of cationic amphiphiles at different time points over 72 h. Each specimen was 
assayed with three replicates. Error bars represent the SEM. Data show the mean values 
± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by one-
way ANOVA with Bonferroni post-test. 
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In many cases, a long PEG linker is preferred for the retention of cellular 
functions.86,87 However, the fast dissociation rate of C18 lipo (EG)48 from RBCs surface 
in vivo suggests that hydrophobic interaction alone is insufficient for the retention of 
payload with the long PEG linker. Since the plasma membranes are negatively charged, 
we postulate that a positively-charged lipid tail would offer electrostatic attraction besides 
hydrophobic interaction and thus prolong the retention time of long PEG conjugated 
amphiphiles on the plasma membranes. We synthesized a cationic C18 lipid and 
conjugated it with fluorescein-labeled long PEG spacer (PEG 2000 averagely equals to 
45 EG units) (Figure 4-4 (a)). The retention kinetics of cationic C18 lipo (EG)45 was 
dramatically improved under ex vivo static conditions (Figure 4-4 (b)). More importantly, 
cationic lipid significantly prolonged circulation half-life of amphiphiles conjugated with 
long PEG spacer in vivo as compared to the original phospholipid-modified analogs, 
characterized by a 40-fold improvement in retention half-life on RBCs. (Figure 4-4 (c-e)). 
24 hours after injection, only 24.3 % of cationic amphiphile was released from RBCs, as 
compared to 72.2% of anionic counterpart. There were a considerable amount of cargos 
remaining inserted on RBCs even after 48 hours of circulation. We concluded that a 
cationic lipid design facilitated the long-term retention of amphiphiles anchored on RBCs 
during circulation. 
4.4 Conclusions 
In summary, we studied the structural factors that affected the retention kinetics of 
lipid-based amphiphiles anchored on RBCs. The results revealed that longer diacyl lipid 
contributed to more stable retention kinetics of amphiphiles, while shorter PEG spacers 
had more profound impact on the stability of amphiphiles anchored on RBCs in vitro and 
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in vivo. In addition, we identified that fluid shear stress accelerated the release of 
membrane-anchored amphiphiles from RBCs and serum albumin was a dominant factor 
that controlled the retention kinetics of amphiphiles loaded on RBCs as well. Furthermore, 
in contrast to an anionic lipid modification, a cationic lipid conjugation to long PEG block 
led to a 40-fold extension in circulation half-life on RBCs in vivo, indicating that a cationic 
structure design of amphiphile was preferred for long-term retention on RBCs. This study 
underscored the rational structural design in the retention kinetics of membrane-anchored 
amphiphiles during systemic circulation, and these findings might be of great interest and 
significance for the advancement of cell-based drug delivery.  
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CHAPTER 5 LACE MOLECULAR VACCINE WITH TLR7/8 ADJUVANT BOOSTER 
TO ENHANCE IMMUNOGENICITY 
5.1 Introduction  
Systemic lupus erythematosus (SLE) is an autoimmune disease where the host 
immune system wrongly mounts immune attacks against a large part of healthy tissues. 
In SLE patients, elevated serum levels of interferon-α (IFN-α) are closely related to 
disease activity and severity.50 The increased levels of IFN-α can be induced by DNA and 
RNA viruses and immune complexes (ICs) that consist of autoantibodies specific to 
endogenous DNA- and RNA-derived self-antigens.50 In innate immunity, TLR7 and TLR9 
signaling can respectively sense mammalian RNA and DNA in the forms of ICs via 
pathogen-associated molecular patterns (PAMPs) and thus induce IFN-α production in 
plasmacytoid dendritic cells (pDC).13,88 Accordingly, inhibitors specific to TLR7 and TLR9 
can be utilized to suppress IFN-α production and thus treat SLE patients. To date, a series 
of oligonucleotide-based inhibitors of TLR signaling have been developed.50,55 To 
leverage the “albumin-hitchhiking” delivery approach, we evaluated the therapeutic 
efficacy of lipid-modified ODN A151 which showed improved immunosuppressive activity 
in inhibiting TLR9-mediated immune activation when compared to the unmodified 
counterpart.  
To further expand the pool of lipo suppressive ODNs, we set out to investigate the 
therapeutic benefits of lipid-modified TLR7 inhibitor. TLR7 is an endosomal receptor 
which binds viral single-stranded RNA such as RNA of hepatitis B virus, or synthetic 
guanine-rich RNA base analogs such as R848 and imiquimod (IMQ).89,90 As one of the 
lead compounds of TLR7 agonists, IMQ has been approved by FDA for topical application, 
which is effective in treating several major skin tumors and cutaneous metastases.91,92 
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To evaluate the efficacy of lipid-modified immunoregulatory sequence 954 (lipo IRS 954), 
a dual inhibitor of TLR7 and TLR9 signaling,50 we used IMQ as a primary ligand to induce 
TLR7-mediated immune activation.  
Surprisingly, we found that lipo IRS 954 enhanced TLR7-mediated activation 
instead of showing TLR7-specific immunosuppression. The immune enhancement was 
also observed in another potent TLR7-specific antagonist, 20-mer thymidine 
oligodeoxynucleotide (T20),90 showing that lipid-modified T20 (lipo T20) also significantly 
improved immune activation of IMQ. Interestingly, in the absence of serum albumin, lipo 
T20 markedly inhibited IMQ-induced activation in Raw-Blue cells, suggesting an 
indispensable role of albumin in the reversal of biological properties of lipo T20. Moreover, 
bovine serum albumin (BSA)-T20 conjugate, which was obtained via covalently 
conjugating T20 to BSA, exhibited potent immunosuppression in TLR7-mediated immune 
activation. Therefore, lipid modification converted the oligonucleotide-based TLR7 
inhibitors into TLR7 adjuvant boosters in the presence of albumin. Because of its small 
molecular size, unformulated IMQ injected subcutaneously showed little LN accumulation. 
Instead, IMQ tends to diffuse into the bloodstream and activate the immune system 
nonspecifically. We reasoned that lipo T20, with intrinsic LN-targeting capability via 
“albumin-hitchhiking”, might be able to enhance the adjuvant activities of IMQ, allowing 
dose-sparing and reducing toxicity. As expected, subcutaneous administration of 
“IMQ/protein antigen” vaccine laced with lipo T20 in mice resulted in a five-fold increase 
in T-cell priming and enhanced antibody response in comparison to the parent vaccine. 
Accordingly, lacing vaccine formula with the adjuvant booster is a novel and simple 
approach to enhance the immunogenicity of molecular vaccines. 
70 
 
5.2 Materials and methods 
5.2.1 Materials  
All reagents and commercially available compounds for DNA synthesis were 
purchased from Glen research (Sterling, VA) or Chemgenes (Wilmington, MA) and used 
following the manufacturer’s instructions. 3’- Fluorescein amidite (FAM) labeled controlled 
pore glass was purchased from Allele Biotechnology (San Diego, CA). Fatty acid-free 
BSA was purchased from Sigma-Aldrich. Ovalbumin protein was purchased from 
Worthington Biochemical Corporation (Lakewood, NJ). Murine MHC class I tetramer was 
obtained from MBL international Corporation (Woburn, MA). Antibodies were purchased 
from eBioscience (San Diego, CA) or BD Bioscience (San Jose, CA). Imiquimod, 
resiquimod, gardiquimod were purchased from Cayman Chemical Company (Ann Arbor, 
MI). 1-(4-(Aminomethyl)benzyl)-2-butyl-1Himidazo[4,5-c]quinolin-4amine dihydrochloride 
was bought from Synnovator, Inc (Durham, NC). CL075, TLR8-506, poly I:C and all cell 
lines were purchased from InvivoGen (San Diego, CA). Cy5-labeled T20 was purchased 
from IDT (Coralville, Iowa). All other reagents were from Sigma-Aldrich and used as 
received except where otherwise noted.  
5.2.2 Synthesis of diacyl lipid phosphoramidite  
The diacyl lipid phosphoramidite was synthesized as previously described.2 A 
solution of stearoyl chloride (6.789 g, 22.41 mmol) in 1,2-dichloroethane (50 mL) was 
added dropwise to a solution of 1,3-diamino-2-dydroxypropane (1.0 g, 11.10 mmol) in the 
presence of 1,2-dichloroethane (100 mL) and triethylamine (2.896 g, 22.41 mmol). The 
reaction mixture was stirred for 2 hours at 25 °C and then heated at 70 °C overnight. The 
reaction mixture was then cooled to 25 °C, filtered, and the solid was sequentially washed 
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with CH2Cl2, CH3OH, 5% NaHCO3 and diethyl ether. The product was dried under 
vacuum to give the intermediate product as a white solid (yield: 90%). 1H NMR (300 MHz, 
CDCl3, ppm): δ 6.3 (m, 2H), 3.8 (m, 1H), 3.4-3.2 (m, 4H), 2.2 (t, 4H), 1.6 (m, 4H), 1.3-1.2 
(m, 60H), 0.9 (t, 6H). The intermediate product (5.8g, 9.31mmol) and N, N-
Diisopropylethylamine (DIPEA, 4.2mL, 18.62mmol) was then suspended in anhydrous 
CH2Cl2 (100 mL). The mixture was cooled on an ice bath and 2-Cyanoethyl N, N-
diisopropylchlorophosphoramidite (8.6 mL, 0.47 mmol) was added dropwise under dry 
nitrogen. After stirring at 25 °C for 1 hour, the solution was heated to 60 °C for 90 min. 
The solution was washed with 5% NaHCO3 and brine, dried over Na2SO4 and 
concentrated under vacuum. The final product was isolated by precipitation from cold 
acetone to afford 4 g (55% yield) lipid phosphoramidite as a white solid. 1H NMR (300 
MHz, CDCl3): δ 6.4 (m, 2H), 3.9 (m, 2H), 3.8 (m, 2H), 3.6 (m, 2H), 3.0-2.9 (m, 2H), 2.6 (t, 
2H), 2.2 (m, 4H), 1.6 (m, 6H), 1.3-1.2 (m, 72H), 0.9 (t, 6H). 31P NMR (CDCl3): 154 ppm. 
5.2.3 Synthesis and purification of oligonucleotides  
All ODN sequences were synthesized using an ABI 394 DNA synthesizer on a 1.0 
micromole scale. All lipophilic phosphoramidites were conjugated as a final ‘base’ on the 
5’ end of oligos. Lipophilic phosphoramidite was dissolved in dichloromethane and 
coupled to oligos in DNA synthesizer (15 min coupling time). After the synthesis, DNA 
was cleaved from the solid support, deprotected, and purified by reverse phase HPLC 
using a C4 column (BioBasic-4, 200mm x 4.6mm, Thermo Scientific), 100mM 
triethylamine-acetic acid buffer (TEAA, pH 7.5)-methanol (0-5 min, 50-80%; 5-15 min, 80-
100%) as an eluent. Lipophilic ODNs typically eluted at 13 min while unconjugated oligos 
eluted at 7 min. Fluorescein-labeled ODNs were synthesized using 3’-(6-Fluorescein) 
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tagged controlled pore glass. Lipid-conjugated IRS 954 (5’-tgctcctggaggggttgt-3),50 T20 
(5’-tttttttttttttttttttt-3’),90,93,94 ODN 2087 (5’- tcctgagcttgaagt-3’)95 CpG ODN 1826 (5’-
tccatgacgttcctgacgtt-3’)26 (phosphorothioate linkage) were synthesized using the above 
method. 
5.2.4 In vitro TLR reporter cells stimulation  
HEK-Blue™-mTLR7, mTLR8, hTLR7, hTLR8, and RAW-BlueTM cells were 
purchased from InvivoGen and were used to evaluate bioactivities of lipo ODNs and TLR 
7/8 ligands in vitro. All these cell lines were cultured with DMEM supplemented with 10% 
FBS, 1% P/S and 100 μg/mL Normocin at 37 °C with 5% CO2. In a typical procedure, 2 
μM IMQ and 1 μM unmodified T20 or lipo T20 (or lipo IRS 954 or lipo ODN 2087) were 
added to InvivoGen HEK-Blue™ murine or human TLR7/8 or RAW-Blue™ mouse 
macrophage reporter cells, both of which are engineered with secreted embryonic 
alkaline phosphatase (SEAP) reporter gene. After incubating for 24 h, SEAP levels were 
quantified by developing supernatants with QuantiBlue™ substrate for 1 h and reading 
absorption at 620 nm, following manufacturer’s instructions.  
5.2.5 In vitro cellular uptake and confocal imaging  
DC 2.4 cells were cultured with RPMI-1640 supplemented with 10% FBS and 1% 
P/S; Raw-Blue cells were cultured as previously described. 1 µM FAM-labeled unmodified 
T20 or lipo T20 at 37 °C for 12 h. After incubation, cells were washed twice with 1 x PBS 
by centrifuge at 800X g for 5 min prior to flow cytometry quantification. To visualize in vitro 
cellular uptake, DC 2.4 cells or Raw-Blue cells were cultured and incubated under the 
same experimental conditions and were subjected to confocal imaging by Zeiss LSM 510 
microscope. To investigate endocytosis pathways, DC 2.4 cells seeded in 12-well plates 
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(5 X 105 cells/well) were pretreated with endocytic inhibitors at 37 °C for 30 min in Opti-
MEM and then treated with 1 μM Alexa-647 BSA or 1 μM FAM-labeled T20 and Lipo T20 
at 37 °C for 2 h. Inhibitors: 5 μg/mL Filipin; 50 μM EIPA; 300mM Sucrose were tested.  
5.2.6 Albumin-ODN conjugates  
Thiol-terminated T20 or CpG was synthesized by solid-phase coupling of 
fluorescein-labeled T20 or CpG with C6 S-S CE phosphoramidite (Thiol-Modifier C6 S-S, 
ChemGenes) at the 5’ end of the oligo. 27 mg Bovine serum albumin (BSA, 50 mg/μL in 
PBS) was co-dissolved with 0.32 mg N-(β-Maleimidopropyloxy) succinimide ester (BMPS, 
30mg/ml in DMSO, Aldrich) and the mixture was agitated at RT for 2h. Extra BMPS was 
removed by diluting in PBS solution and passing the mixture through a PD MidiTrap G-
25 desalting column (GE Healthcare) and concentrated and further purified by centrifuge 
filter tube (30K MWCO). 125 nmol of 5’-disulfide-modified fluorescein-T20 or CpG was 
pre-activated by 1000 nmol TCEP (3,3’,3’’-Phosphanetriyltripropionic acid, 100mM in 
deionized water) and then purified through centrifuge filter tube (30K MWCO). 
Subsequently, activated T20 or CpG was added to the modified-BSA solution. The 
mixture was agitated overnight at RT and unconjugated T20 or CpG was removed by 
configuring filter tube (30K MWCO); free T20 or CpG removal was confirmed by size-
exclusion chromatography. 
5.2.7 Preparation of murine splenocytes  
Spleens were freshly collected from mice and were cut into small pieces. A plunger 
end of a syringe was used to further disassemble spleen tissues into single cells. The cell 
suspension was subsequently filtered and washed. Lysing buffer was utilized to remove 
excessive red blood cells. After twice washes, 95% viability of splenocytes was confirmed 
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by trypan blue. Splenocytes were resuspended in RPMI-1640 supplemented with 10% 
FBS and 1% P/S. Splenocytes were seeded at 1 x 106 cells/ml in 200μL in a 96-well plate. 
Splenocytes were treated with 2 μM IMQ alone or plus 1 μM T20 or lipo T20 for 24 h 
under culturing conditions.  
5.2.8 Preparation of primary human cells  
Whole blood was obtained from Red Cross where healthy volunteers had provided 
informed consent to donate blood. PBMC were isolated by density gradient centrifugation 
using Histopaque-1077 (Sigma-Aldrich). The mononuclear cells were washed twice with 
cold PBS (1X) and resuspended in completed RPMI-1640 supplemented with 10% FBS 
and 1% penicillin/streptomycin. PBMC were seeded at 2 x 106/ml in 200 μL in a 96-well 
plate. Plasmacytoid DC (pDC) monocytes were isolated from PBMC by immunomagnetic 
bead positive selection using BDCA-4 according to manufacturer’s instructions. Briefly, 
PBMC were first blocked with human FcR blocking reagent and then incubated with 
immunomagnetic MACS microbeads, and the labeled cells were collected with Miltenyi 
columns. The positively selected cells were resuspended in complete RPMI and seeded 
at 1 x 106 cells/ml in 200μL in a 96-well plate. pDC purity and viability from positively 
isolated cells and populations of cells were determined by flow cytometry. 
5.2.9 Determination of secreted cytokines   
Supernatants collected from splenocytes suspension or human PBMC suspension 
after incubation were separately analyzed for IL-6, IL-12p40, TNF-α and IFN-α by ELISA 
following manufacturer’s instructions.  
5.2.10 In vivo immunization  
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C57BL/6 mice (6-8 weeks) were immunized by a homologous prime-boost regimen: 
animals were primed on day 0 and boosted on day 14 with 50 µg Ovalbumin and 15 µg 
IMQ mixed with or without 6.2 nmol lipo T20 dissolved in PBS. The volume of all vaccine 
injections was 100 µL/animal. All injections were performed subcutaneously at the base 
of the tail.  
5.2.11 Tetramer Staining  
Seven days after the final immunization, blood samples were collected. Red blood 
cells were lysed by ACK lysing buffer. Cells were then blocked with Fc-blocker (anti-
mouse CD16/CD32 monoclonal antibody) and stained with SIINFEKL loaded 
phycoerythrin-labeled tetramers (Beckman Coulter) and anti-CD8-APC (ebioscience) for 
30 min at 4 oC. Cells were washed twice, resuspended in FACS buffer, and analyzed on 
Attune Focus flow cytometer. Analysis typically gated on live CD8+, Tetramer positive 
cells. 
5.2.12. Intracellular cytokine staining  
Peripheral blood was lysed with ACK buffer and washed with PBS twice. Purified 
cells were seeded in 96-well round-bottomed plates and pulsed with 10 μg/mL OVA 
peptide SIINFEKL for 2 h at 37 °C in T-cell media (RPMI-1640, 10% FBS, 50 μM β-
mecaptoethanol, 1% P/S), followed by the addition of brefeldin A for 4 hours. Cells were 
stained with anti-CD8-APC and then fixed using Cytofix following the manufacturer’s 
instructions. Next, cells were washed and permeabilized. Intracellular staining for anti-
IFN-γ-PE and anti-TNF-α-FITC was performed following the manufacturer’s instructions 
and cells were analyzed by Attune Focus flow cytometer. 
5.2.13 ELISA for OVA-specific IgG   
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Mice were bled, and blood samples were collected. Serum anti-OVA IgG levels 
were determined by ELISA: 96-well plates were coated overnight with 10 μg/ml OVA in 
PBS and blocked with 1% BSA in PBS. After incubation of serum samples for 1h at a 
series of dilutions, plates were washed with PBS/1% Tween-20. Goat anti-mouse IgG 
conjugated to Horseradish peroxidase (HRP) was added at 1 μg/ml for 30min. Plates 
were washed with PBS/1% Tween-20 and ELISA was developed by (3,3’,5,5’-
Tetramethylbenzidine) (TMB, ebioscience). The reaction was stopped by 1M H2SO4 and 
the absorbance was read at 450 nm and 570 nm using a plate reader. 
5.2.14 Statistical analysis  
All plots show mean values and error bars represent the SEM. One-way analysis 
of variance (ANOVA), followed by a Bonferroni post-test, was used to compare >2 groups. 
*, p<0.05; **, p<0.01; ***, p<0.001; ns, not significant unless otherwise indicated. 
Statistical analysis was performed using GraphPad Prism software (San Diego, CA). 
5.3 Results and discussion 
5.3.1 Lipid conjugation specifically reverses oligonucleotide-based TLR7 
inhibitors 
Our previous finding demonstrated that lipid-modified oligonucleotide-based TLR9 
inhibitor was more potent and efficacious than unmodified oligo in targeting LNs and 
suppressing CpG-induced immune activation. Inspired by this study, we aimed to take 
advantage of lipid functionalization in other oligonucleotide-based TLR inhibitors to further 
expand the pool of lipo suppressive ODNs. We set out to investigate the therapeutic 
efficacy of lipid-modified IRS 945 in suppressing TLR7-mediated immune activation and 
alleviating the severity of SLE. As shown in Figure 5-1 (a), we first used imiquimod (IMQ) 
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to stimulate TLR7-mediated immune activation in Raw-Blue reporter cells and determined 
immunosuppressive capability of unmodified or lipo IRS 954 by quantifying the level of 
TLR7-induced NF-κB activation. However, the results showed that lipo IRS 954 markedly 
enhanced TLR7-mediated activation, while the unmodified IRS 954 itself remained 
immunosuppressive toward TLR7 signaling (Figure 5-1 (b)).  
 
Figure 5-1. (a) Structure of imiquimod (IMQ) and single-stranded DNA sequence 
of IRS 945 and lipo IRS 954, (b) Raw-Blue cells were stimulated with 2 μM IMQ alone or 
IMQ + 1 μM IRS 954 or lipo IRS 954 for 24 h, (c) Raw-Blue cells were stimulated with 2 
μM IMQ alone or plus 1 μM T20 or lipo T20 for 24 h, (d) Raw-Blue cells were stimulated 
with 10 μg/ml Poly I:C,  2 μM IMQ and  100 nM CpG ODN 1826 alone,  or plus 1 μM lipo 
T20 respectively for 24 h. Data show the mean values ± SEM. *, p < 0.05; **, p < 0.01; 
***, p < 0.001; ****, p < 0.0001; ns, not significant by one-way ANOVA with Bonferroni 
post-test. 
Based on these compelling results, we hypothesized that lipid modification might 
be used to reverse the immunological properties of oligonucleotide-based TLR7 inhibitors. 
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To test this hypothesis, we conjugated the C18 lipid tail to another classic oligonucleotide-
based TLR7 inhibitor, 20-mer thymidine oligodeoxynucleotide, to generate lipo T20 and 
then tested it following previous experimental settings. Similar to lipo IRS 954, lipo T20 
enhanced the immunostimulatory activities of IMQ by 5 folds. In contrast, unmodified T20 
was suppressive toward IMQ stimulation, lowering the NF- κB activation by 2 folds 
(Figure 5-1 (c)). The enhancement of NF-κB activation by lipo T20 appeared to be TLR7 
specific, as no enhancement was observed when Raw-Blue cells were stimulated by CpG 
ODN (a TLR9 ligand) and Poly I:C (a TLR3 ligand) (Figure 5-1 (d)). Collectively, we found 
that lipid conjugation could specifically reverse the inhibitory effect of oligonucleotide-
based TLR7 inhibitors.   
5.3.2 The role of albumin in the mechanism of action  
 
Figure 5-2. (a) Raw-Blue cells were stimulated with 2 μM IMQ alone or plus 1 μM 
lipo T20 or lipo (EG)48 for 24 h. (b) Flow cytometry analysis of DC 2.4 cells treated with 
1 μM of FAM-T20 or FAM-lipo T20 for 12 h or 24 h at 37 °C. (c) Raw-Blue cells were 
stimulated with 2 μM IMQ alone or plus 1 μM lipo T20 or 5 μM T20 for 24 h. (d) 
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Representative confocal images of DC 2.4 cells treated with 1 μM Cy5-labeled T20 and 
FAM-labeled lipo T20 simultaneously. Scale bar: 10 μm. Data show the mean values ± 
SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by one-
way ANOVA with Bonferroni post-test or unpaired Students’ t-test. 
Structurally, lipo T20 might be stimulatory due to the lipid moiety. To test whether 
lipid tail can stimulate cells, we conjugated the same diacyl lipid to oligo-mimicking 
“hexaethyleneglycol” blocks via DNA synthesizer. The amphiphilic polymer lipo (EG)48 
has a length comparable to lipo T20.  Lipid tail itself did not affect IMQ-induced activation 
(Figure 5-2 (a)). According to our previous studies, lipid conjugation typically resulted in 
increased cellular uptake. The results here also showed that DC 2.4 cells preferentially 
internalized more lipo T20 than unmodified T20 over 24 h incubation (Figure 5-2 (b)). We 
then speculated that quantitatively increased cellular uptake of T20 might contribute to 
the qualitative reversal of lipo T20’s immunosuppressive properties. However, high-dose 
T20, five times more concentrated than lipo T20, exhibited significantly enhanced 
inhibition in IMQ-elicited activation (Figure 5-2 (c)), suggesting an enhanced uptake was 
not responsible for the improved stimulation. In addition, lipid modification did not alter 
cellular localization of T20, as demonstrated in confocal imaging of DC 2.4 cells treated 
with 1 μM Cy5-labeled T20 and FAM-labeled lipo T20 simultaneously (Figure 5-2 (d)).  
A previous work reported that poly-thymidine could interact with TLR7 ligands like 
IMQ.90 Therefore, we postulated that lipo T20, with uptake-facilitating lipid tail, might 
promote cellular uptake of TLR7 ligands via ODN-drug intercalation and subsequently 
enhanced IMQ-induced activation. To verify this possibility, we used a functionalizable 
TLR7 analog of IMQ, “1-(4-(Aminomethyl) benzyl)-2-butyl-1Himidazo[4,5-c]quinolin-
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4amine” (IMDQ), for quantification of cellular uptake and fluorescence imaging. Flow 
cytometry data indicated that neither T20 nor lipo T20 increased cellular uptake of FITC-
labeled IMDQ (Figure 5-3 (a)). Besides, confocal imaging indicated that IMDQ was 
primarily in the endosomal-lysosomal compartment in the presence of T20 or lipo T20 
(Figure 5-3 (b)). Taken together, the data we showed here demonstrated that lipid 
conjugated T20 was a TLR7 adjuvant enhancer which dramatically improved the 
immunostimulatory effect of IMQ. 
 
Figure 5-3. (a) Structure of FITC labeled-IMDQ and flow cytometry analysis of 
Raw-Blue reporter cells treated with 2 μM FITC-IMDQ alone or in combination with 1 μM 
T20 or lipo T20, (b) Representative confocal images of DC 2.4 cells which were treated 
with 2 μM Cy5-labeled IMDQ alone or in combination with 1 μM T20 or lipo T20 for 24 h 
and then washed and stained with 50 nM LysoTracker Green and 300 nM DAPI (4’, 6-
diamidino-2-phenylindole) following manufacturer’s instructions. Scale bar: 10 μm. Data 
show the mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; 
ns, not significant by one-way ANOVA with Bonferroni post-test. 
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Figure 5-4. (a) Flow cytometry analysis of DC 2.4 cells treated with endocytosis 
inhibitors for 30 min, followed by 1.5 h incubation with 1 μM FAM-labeled T20 or lipo T20 
or 1 μM Alexa-647 BSA respectively, (b) Raw-Blue reporter cells were stimulated with 2 
μM IMQ alone or in combination with 1 μM T20 or lipo T20 under FBS-free and normal 
culture conditions respectively for 24 h, (c) Flow cytometry analysis of Raw-Blue reporter 
cells which were cultured with complete or FBS-free medium separately for 24 h and then 
stained with Annexin V and PI for cell apoptosis assay, (d) Raw-Blue reporter cells were 
stimulated with 2 μM IMQ alone or in combination with 1 μM lipo T20 pre-complexed with 
BSA at 1: 1 and 1: 2 ratio respectively under FBS-free (O/F) condition for 24h; Meanwhile, 
Raw-Blue reporter cells were stimulated with 2 μM IMQ  alone or in combination with 1 
μM lipo T20 under FBS-supplemented (W/F) condition for 24 h. Data show the mean 
values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant 
by one-way ANOVA with Bonferroni post-test. 
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As lipo T20 contained a lipophilic domain which enabled avid “albumin-binding”, it 
was reasonable to ask the question of whether albumin was playing a role in enhancing 
IMQ stimulation by lipo T20. In fact, the culture medium was normally supplemented with 
fetal bovine serum (FBS) containing excessive albumin relative to the quantity of lipo T20 
utilized, so it was highly possible that lipo T20 would bind to serum albumin (FBS) once 
added to culture medium. As part of the proof to support this hypothesis, we observed 
that endocytosis pathway of lipo T20 exactly mimicked that of BSA, which was 
internalized mainly via macropinocytosis (EIPA) and clathrin-mediated endocytosis 
(Sugar) in DC 2.4 cells (Figure 5-4 (a)). Our observation agreed with previous studies on 
endocytosis of lipid-modified ODN conjugates and albumin.96-98 To further determine the 
role of albumin in the enhanced stimulation of IMQ, Raw-Blue cells were seeded overnight 
and then stimulated as previously described using the serum-free medium. Interestingly, 
lipo T20 completely suppressed IMQ-induced NF-κB activation under FBS-free culture 
conditions, indicating that albumin played an important role in the effect of lipo T20 on 
TLR 7 stimulation (Figure 5-4 (b)). Meanwhile, we ruled out the cell viability as a potential 
factor for downregulated NF-κB stimulation by confirming that the survival rate of Raw-
Blue cells was unchanged under the FBS-free culture condition (Figure 5-4 (c)).  
Since lipo ODN is able to hijack albumin and subsequently accumulates in APCs 
residing in LNs,2 forming stable albumin-lipo ODN complexes in physiological condition 
is a prerequisite for survival on their thorny way to LNs and lymphoid APCs. Similarly, lipo 
T20 should be able to complex with albumin under FBS-supplemented culture condition 
before being transported into cells. Besides, our research into erythrocytes insertion 
revealed that amphiphilic polymer was unable to massively insert into the plasma 
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membrane in the presence of blood serum. Collectively, these reasonings pointed to a 
“fact” that lipo T20 was transferred into cells in the form of lipo T20-albumin complex. To 
verify our postulation, we pre-incubated lipo T20 with BSA at a ratio of 1:1 and 1:2 for 1h 
and then treated pre-seeded Raw-Blue cells with 1 μM BSA-complexed lipo T20 under 
FBS-free condition. The results clearly showed that lipo T20’s capability of suppressing 
IMQ-induced activation was progressively abrogated as the ratio of pre-complexed BSA 
increased (Figure 5-4 (d)). Hence, we confirmed that the reversal of lipo T20’s biological 
capability of inhibiting TLR7 signaling primarily resulted from albumin which formed 
albumin-lipo T20 complex via noncovalent interaction.  
 
Figure 5-5. (a) Representative confocal images of Raw-Blue reporter cells treated 
with 1 μM FAM-labeled T20 or FAM-labeled lipo T20 under FBS-supplemented condition, 
or (b)under FBS-free condition, and then washed and stained with 50 nM LysoTracker 
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Red following manufacturer’s instructions. Scale bar: 10 μm. (c) Raw-Blue cells were 
stimulated with 2 μM IMQ alone or in combination with 1 μM disulfide bond-linked T20 or 
lipo T20 or BSA-T20 conjugate under FBS-supplemented condition, (d) under FBS-free 
condition, for 24 h. Data show the mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 
0.001; ****, p < 0.0001; ns, not significant by one-way ANOVA with Bonferroni post-test. 
Additionally, we also illustrated that both T20 and lipo T20 colocalized with 
lysosomes regardless of the presence of FBS, suggesting that albumin did not 
significantly affect lipo T20’s intracellular destination (Figure 5-5 (a-b)). However, a 
covalently-synthesized BSA-T20 conjugate failed to reverse the intrinsic properties of T20 
under both FBS-supplemented and FBS-free culture conditions as it greatly suppressed 
IMQ-induced activation (Figure 5-5 (c-d)). Accordingly, the reversal of lipo T20’s 
immunological property was more than due to the endocytosis pathway via hijacking 
albumin and was not due to quantitatively increased cellular uptake.  
5.3.3 Optimization of TLR7 adjuvant booster  
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Figure 5-6. (a) Structure of C18 diacyl lipid conjugated poly-oligo(dT) and C14 
diacyl lipid conjugated T20, (b) Raw-Blue reporter cells were stimulated with 2 μM IMQ 
alone or with 1 μM lipo T10, lipo T20, lipo T25 and lipo T50 for 24 h, (c) Raw-Blue reporter 
cells were stimulated with 2 μM IMQ alone or in combination with 1 μM C14 diacyl lipid-
modified T20 or C18 diacyl lipid-modified T20 for 24 h, (d) Raw-Blue cells were stimulated 
with 2 μM IMQ alone or in combination with 1 μM lipo T10, lipo T20, lipo T25 and lipo T50 
for 24 h, (e) Structure of 3’-and 5’-modified Cholesterol T20, (f) HEK mTLR7 reporter cells 
were stimulated with 2 μM IMQ alone or in combination with 1 μM 3’- and 5’-modified 
Cholesterol T20 for 24 h, (g) HEK mTLR8 reporter cells were stimulated with 2 μM R848 
alone or in combination with 1 μM 3’-and 5’- modified Cholesterol T20 for 24 h.  Data 
show the mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; 
ns, not significant by one-way ANOVA with Bonferroni post-test. 
To optimize TLR7 stimulation enhancing efficacy, we synthesized a series of lipo 
poly-oligo-deoxythymidine (poly-Oligo(dT)) to treat Raw-Blue cells along with IMQ 
(Figure 5-6 (a)). As shown in Figure 5-6 (b), lipo T20 or lipo T25 mixed with IMQ induced 
the highest level of NF-κB stimulation. In contrast, lipo T10 showed little effect on IMQ-
mediated activation, while lipo T50 slightly suppressed TLR7 signaling. ODNs conjugated 
with short diacyl lipids, such as C12 and C14 lipid chains, were less effective in targeting 
LNs due to relatively weak hydrophobic interaction between lipid tails and albumin.2 
However, we observed that C14 lipid-modified T20 gave a comparable level of immune 
activation when mixed with IMQ in vitro (Figure 5-6 (c)). In addition, we found that lipo 
T20 was unable to enhance IMQ-induced activation once the ratio of lipo T20 to IMQ was 
less 1:10, while no further potency-enhancing effect was observed when this ratio was 
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greater than 5:10 (Figure 5-6 (d)). Although most lipo ODNs were modified at 5’ terminal 
of ODN due to simplicity and cost of synthesis, 3’-terminal might give different levels of 
effects, as reported on the modification of CpG oligonucleotides. To test whether lipid 
modification at 3’ terminal of T20 would affect immune modulation, we synthesized 5’- 
and 3’-conjugated lipo T20 by using a 5’-cholesterol phosphoramidite and a 3’-cholesterol 
beads respectively (Figure 5-6 (e)). Since T20 itself was a TLR8 booster as well as a 
TLR7 inhibitor, we used murine TLR7 and TLR8 reporter cells separately for NF-κB 
stimulation assay. The results revealed that both 5’- and 3’-modified T20s were able to 
significantly enhance IMQ-induced stimulation in murine TLR7 cells, while both were 
functionally compromised after modification and unable to activate resiquimod (R848)-
elicited murine TLR8 signaling (Figure 5-6 (f-g)). Together, these data demonstrated that 
lipid poly-oligo(dT) with 20~25-mer was the optimal structure to induce the highest level 
of TLR7-mediated NF-κB activation, and T20 modified with less hydrophobic lipid tail, 
compared to C18 lipid chain, at either 5’ or 3’ terminal was able to reverse the TLR7-
specific suppression.  
5.3.4 Immune modulation on TLR7 and TLR8 reporter cells  
To investigate differential modulation of lipo T20 on TLR7 and TLR8, we evaluated 
half-maximal effective concentration (EC50) and potency of several classic TLR7/8 
ligands in murine TLR7 and TLR8 reporter cells. The results implied that lipo T20 
significantly lowered EC50 and improved the potency of IMQ, CL075, and R848, while 
T20 functioned in an opposed trend in murine TLR7 reporter cells (Figure 5-7 (a-c)). On 
the contrary, T20 was able to activate murine TLR8 only if mixed with a high dose of 
TLR7/8 ligands, while lipo T20 showed no effect (Figure 5-7 (d-f)). To determine the 
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levels of overall stimulation, we repeated the titration experiments in Raw-Blue reporter 
cells. Similar to that in murine TLR7 reporter cells, lipo T20 improved the potency and 
EC50 of these ligands and T20 suppressed their NF-κB stimulation in Raw-Blue reporter 
cells, indicating that although lipo T20 and T20 exhibited opposite stimulation toward 
TLR7 and TLR8, lipo T20 enhanced the overall NF- κB stimulation. These data clearly 
demonstrated lipo T20, but not T20, could act as an adjuvant enhancer to improve the 
immune stimulation of TLR7 (Figure 5-7 (g-i)).  
 
Figure 5-7. (a-c) HEK mTLR7 reporter cells were stimulated with IMQ, CL075, 
R848 at indicated concentrations alone or in combination with 1 μM T20 or lipo T20 for 
24 h, (d-f) HEK mTLR8 reporter cells were stimulated with IMQ, CL075, R848 respectively 
at indicated concentrations alone or in combination with 1 μM T20 or lipo T20 for 24 h, 
88 
 
(g-i) Raw-Blue reporter cells were stimulated with IMQ, CL075, R848 respectively at 
indicated concentrations alone or in combination with 1 μM T20 or lipo T20 for 24 h. 
Human and murine TLR7/8 shared many similarities in genetic sequence and 
function. To determine whether the above results could be translated to human cells, we 
stimulated human TLR7 reporter cells with several lipid-modified oligonucleotides. The 
results showed that besides lipo T20 and lipo IRS 954, lipid-modified ODN 2087, originally 
a human TLR7 and TLR8 inhibitor, also remarkably enhanced IMQ-induced NF-κB 
stimulation (Figure 5-8 (a)). In addition, lipo T20 exhibited significantly better stimulation 
than other lipid-modified oligonucleotides, showing an improved EC50 and potency of 
IMQ in human TLR7 reporter cells (Figure 5-8 (b)). As for human TLR8 signaling, lipo 
T20 did not affect the stimulatory potency of TLR8-506, a human TLR8 ligand. However, 
lipo ODN 2087 suppressed TLR8-506 stimulation. In contrast, T20 remained efficacious 
in potentiating TLR8 signaling in human TLR8 reporter cells (Figure 5-8 (c-d)), especially 
at high TLR8-506 concentrations. Overall, these results suggested the feasibility of 
applying lipo T20 and analogs to human models. 
 
Figure 5-8. (a) HEK hTLR7 reporter cells were stimulated with 2 μM IMQ alone or 
in combination with 1 μM T20 or lipo T20, 1 μM IRS 954 or lipo IRS 954, 1 μM ODN 2087 
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or lipo ODN 2087 respectively for 24 h, (b) HEK hTLR7 reporter cells were stimulated 
with IMQ at indicated concentrations alone or in combination with 1 μM T20 or lipo T20 
for 24 h, (c) HEK hTLR8 reporter cells were stimulated with 1 μg/ml TLR8-506 alone or 
in combination with 1 μM T20 or lipo T20, 1 μM ODN 2087 or lipo ODN 2087 respectively 
for 24 h, (d) HEK hTLR8  reporter cells were stimulated with TLR8-506 at indicated 
concentrations alone or in combination with 1 μM T20 or lipo T20 for 24 h. Data show the 
mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not 
significant by one-way ANOVA with Bonferroni post-test. 
5.3.5 Ex vivo evaluation of adjuvant booster  
 
Figure 5-9. (a-d) Murine splenocytes were stimulated with 2 μM IMQ alone or in 
combination with 1 μM T20 or lipo T20 for 24 h, and the inflammatory cytokines and type 
I IFN secreted by splenocytes including IL-6 (a), IL-12p40 (b), TNF-α (c), IFN-α (d) were 
measured by ELISA, (e) Representative flow cytometry plots of pDC enriched from 
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human PBMC, (f) human pDC cells  were stimulated with 2 μM IMQ alone or in 
combination with 1 μM T20 or lipo T20 for 24 h, and IFN-α secreted by pDC cells was 
determined by ELISA, (g) Human PBMC cells  were stimulated with 60 nM TLR8-506 
alone or in combination with 1 μM T20 or lipo T20 for 24 h, and TNF-α secreted by PBMC 
cells was determined by ELISA. Data show the mean values ± SEM. *, p < 0.05; **, p < 
0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by one-way ANOVA with 
Bonferroni post-test. 
To evaluate the adjuvant enhancing activities of lipo T20 in primary immune cells, 
we isolated splenocytes from mice spleens and stimulated them with IMQ as previously 
described in TLR7/8 reporter cells. Consistent with our previous findings in the reporter 
cells, lipo T20 markedly potentiated the potency of IMQ by upregulating the production of 
NF-κB-signaled pro-inflammatory cytokines including IL-6, IL-12p40, and TNF-α, while 
IMQ mixed with T20 led to a significantly lower level of pro-inflammatory cytokines 
compared with IMQ alone (Figure 5-9 (a-c)). Interestingly, we observed that both T20 
and lipo T20 decreased the production of IFN-α induced by IMQ (Figure 5-9 (d)). As 
secretion of IFN-α from pDC was mainly regulated through IRF7 signaling but 
independent of NF-κB activation,99 the results suggested that lipo T20 primarily intensified 
TLR7-signaled NF-κB activation but was still able to inhibit TLR7-meidated production of 
IFN-α.  
Using human pDC enriched from human PBMC with 55.7% purity (Figure 5-9 (e)), 
we further confirmed that lipo T20 partially conserved T20’s capability of downregulating 
TLR7-mediated activation, evidenced by almost no secretion of IFN-α from pDC treated 
with IMQ and lipo T20 (Figure 5-9 (f)). Interestingly, we observed that lipo T20 was able 
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to significantly increase the production of TNF-α when mixed with TLR8-506 to treat 
human PBMC (Figure 5-9 (g)). However, we demonstrated that lipo T20 had no impact 
on TLR8-mediated NF-κB activation which regulated the production of pro-inflammatory 
cytokines including TNF-α. Although underlying mechanisms remained unknown, one 
possible interpretation was that lipo T20 mixed with TLR8 ligand might simultaneously 
activate various immune cells in PBMC, which led to TLR8-mediated NF-κB activation. 
These data emphasized specific innate immune activation pathways that lipo T20 
possibly acted on, and it also suggested that lipo T20 could be a dual-booster for TLR7 
and TLR8 adjuvants, which might be applied in clinical practice.  
5.3.6 Adjuvant booster enhances immune responses of molecular vaccines in 
vivo 
 
Figure 5-10. (a) Representative flow cytometry plots of H-2Kb/SIINFEKL tetramer 
staining of CD8+ cells, (b) Quantification of H-2Kb/SIINFEKL tetramer staining of CD8+ 
cells, (c) Quantification of IFN-γ-secreting CD8+ T cell determined by intracellular 
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cytokine staining, (d) Quantification of TNF-α-secreting CD8+ T cell determined by 
intracellular cytokine staining, (e) On day 20, serum samples were collected and 
assayed by ELISA for anti-OVA IgG production. Data show the mean values ± SEM. *, 
p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by one-way 
ANOVA with Bonferroni post-test. 
We revealed that lipo T20 improved the stimulatory potency and efficacy of IMQ in 
the presence of albumin. In fact, interstitial space in the body harbors considerable serum 
albumin which circulates through lymphatic system back to bloodstreams.100 Therefore, 
lipo T20 theoretically was able to hijack interstitial albumin and then leverage it for 
intensifying the potency of TLR7/8 ligands in the LNs. Previous studies reported that 
unmodified IMQ showed little accumulation in the LNs while lipo T20 was able to target 
APCs in the LN via ‘albumin-hitchhiking’.2,101 Besides, our data showed that lipo T20 
amplified IMQ-induced immune activation in TLR reporter cells. Thus, we hypothesized 
that subcutaneous administration of lipo T20 would improve the adjuvant effect of IMQ 
and immune activation. To test this hypothesis, we immunized mice with model antigen 
ovalbumin adjuvanted with a low dose of IMQ in the presence or absence of 6.2 nmol lipo 
T20. Unformulated IMQ + OVA did not elicit detectable antigen-specific CD8+ T cells in 
blood, presumably due to the insufficient LN draining of IMQ. However, the addition of 
lipo T20 resulted in an approximate five-fold increase in OVA-specific CD8+ T cells and 
up to a four-fold expansion of IFN-γ-secreting and TNF-α-secreting CD8+ T cells, as well 
as significantly improved OVA-specific IgG titers in mice (Figure 5-10).  
These results demonstrated that lipo T20 could function as a potent TLR7/8 
adjuvant booster to potentiate immune responses induced by the molecular vaccine in 
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vivo. Thus, lacing vaccine formulation with the adjuvant booster represents a novel and 
simple approach to amplify the immunogenicity of subunit vaccines. The concept of 
adjuvant enhancers can be immediately applied to current molecular vaccines adjuvanted 
by TLR7/8 ligands, providing a plug and play approach to catalyze the development of 
next-generation cancer vaccines.   
5.4 Conclusions 
In summary, we found that lipid-modified oligonucleotide-based TLR7/8 inhibitors 
were able to improve the potency and efficacy of TLR7/8 ligands in the presence of 
albumin. We found that these lipo ODNs could tolerate a wide range of sequences, but 
the structurally-optimized lipo poly (dT) (20-25 nucleotides) showed maximal enhancing 
effects. In addition, we found that lipo T20 was also applicable to human cells and was 
able to enhance human TLR7- and TLR8-mediated NF-κB stimulation. However, lipo T20 
still conserved the immunosuppressive capability of reducing TLR7-mediated production 
of IFN-α in both murine and human cells. More significantly, lipo T20 was proved to be a 
powerful adjuvant enhancer in enhancing the immune responses to molecular vaccines, 
as lacing subunit vaccine formulation with lipo T20 led to markedly improved cellular and 
humoral responses in mice. This finding might be broadly applicable in many current 
vaccines, where both efficacy and safety are needed.    
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CHAPTER 6 SUMMARY AND OUTLOOK 
The major focus of this dissertation is to expand the research scope of the 
“albumin-hitchhiking” approach. We mainly studied the therapeutic efficacy and 
immunological properties of a variety of lipid-modified ODNs that were utilized for immune 
modulation through LN-targeting delivery. For stimulatory ODNs, we showed that lipid 
modification compromised the immunological activities of CpG ODNs in vitro, while lipid-
modified class B and C CpG ODNs were able to markedly enhance the immunogenicity 
of subunit vaccines in mice. In addition, lipid modification dramatically increased the 
accumulation of CpG ODNs in LNs and reduced CpG-associated systemic toxicity. 
Collectively, this study highlights the significance of targeted delivery to local LNs and 
suggests that the “albumin-hitchhiking” approach holds great promise in optimizing 
therapeutic efficacy of cancer vaccines while minimizing adjuvants-related side effects. 
On the other hand, lipid modification on suppressive ODN A151 resulted in the greater 
inhibitory capability of suppressing TLR9-mediated immune activation and enhanced 
cellular uptake. Besides, compared to unmodified ODN A151, lipid-conjugated ODN A151 
showed increased LN accumulation and demonstrated markedly improved therapeutic 
efficacy in suppressing immune responses induced by CpG-adjuvanted vaccines in vivo. 
These findings indicate that targeting suppressive ODN to LNs via hitchhiking 
endogenous albumin may be a promising approach to potentiate immunoinhibitory 
properties of suppressive ODN. In future works, we look forward to targeting other 
immune modulators to local LNs to manipulate immune responses for the treatment of 
autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  
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Based on the intrinsic membrane-insertion properties of amphiphilic molecules, we 
developed cell-based delivery strategies for systemic administration of therapeutics. 
Specifically, we studied the structure-dependent stability of lipid-based amphiphiles 
anchored on RBCs. The data revealed that longer diacyl lipid chain and short PEG spacer 
contributed to more stable retention kinetics of amphiphiles loaded on RBCs in vivo. More 
importantly, we observed that cationic lipid-modified amphiphiles exhibited exponentially 
prolonged circulation half-life on RBCs in vivo relative to anionic lipid-conjugated analogs. 
This research demonstrated a simple yet efficient cellular-hitchhiking delivery strategy 
and emphasized the importance of rational structure design in in vivo stability of 
amphiphiles anchored on RBCs. Many research directions may be developed based on 
these findings. For example, loading amphiphilic chemotherapeutic drugs on RBCs 
through spontaneous insertion may significantly extend their circulation half-life in vivo 
and circumvent rapid immune clearance, and thus it may lead to sustained tumor killing 
and achieve remarkable therapeutic efficacy in cancer treatment. In parallel, by 
leveraging immunological properties of RBCs, amphiphilic peptides that hitchhike RBCs 
may evade immune surveillance and stimulation and thus induce systemic tolerance 
towards self-antigens that trigger autoimmunity. Hence, the “RBC-hitchhiking” approach 
may hold great promise in treating autoimmune disorders as well.  
More importantly, we discovered a novel class of lipid-modified oligonucleotide-
based adjuvant booster which could enhance the adjuvant potency of TLR7/8 ligands in 
vitro and in vivo. We explored the underlying mechanism by which lipid modification 
converted oligonucleotide-based TLR7 inhibitors into TLR7 adjuvant boosters. The data 
revealed that albumin was playing a pivotal role in the functional reversal of lipid-modified 
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TLR7 inhibitors. Furthermore, we showed that lipid-modified oligonucleotide-based 
adjuvant booster was applicable to human cells and could enhance human TLR7- and 
TLR8-mediated NF-κB stimulation. More strikingly, the results demonstrated that 
subcutaneous administration of imiquimod-adjuvanted vaccine laced with the adjuvant 
booster in mice markedly enhanced antigen-specific cellular and humoral responses, 
compared to the same vaccine without the adjuvant booster. Current strategies that are 
employed to enhance the immunogenicity and safety of vaccines mainly focus on refining 
the delivery efficiency of therapeutics to manipulate immune responses while minimizing 
systemic toxicity. The concept of adjuvant booster-laced “molecular vaccine cocktail” 
features a simple, novel and effective approach to considerably boosting the potency of 
vaccine adjuvant and subsequently improving the immunogenicity of therapeutic vaccines. 
The future work may further explore the molecular and structural mechanism by which 
adjuvant boosters act on TLR7/8-mediated immune activation. By studying and 
understanding the constitutive mechanisms, we may be able to design and engineer 
biomolecules in a more rational way to modulate immune activation and achieve optimal 
efficacy of cancer vaccines for clinical application. Another future research topic that may 
be derived from this study may focus on the application of adjuvant booster in some 
representative tumor models combined with current cancer vaccines, with the goal to 
reverse tumor-associated immunosuppression and lead to tumor regression. Accordingly, 
we will set out to investigate the efficacy of adjuvant booster in maximizing the 
immunogenicity of cancer vaccines while minimizing systemic inflammatory reactions 
induced by vaccine adjuvants in tumor models.  
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Immunotherapy is emerging as one of the most promising therapeutic strategies 
for cancer treatment in clinical practice. Immunotherapy leverages the host’s immune 
system to attack and kill tumor cells. Rationally-designed cancer vaccines are emerging 
as one of the powerful immunotherapies primarily because of the promise of inducing 
potent anti-tumor immunity and eradicating tumors. To improve the immunogenicity of 
cancer vaccines, vaccine antigens are administered with vaccine adjuvants which can 
robustly activate the innate immune system and subsequently lead to adaptive immune 
responses. However, the major challenge of achieving significant therapeutic efficacy is 
the lack of efficient targeted delivery of vaccine components. By taking advantage of 
endogenous albumin, lipid-modified oligonucleotides-based adjuvants can be efficiently 
transported to draining lymph nodes (dLNs), where a variety of immune cells reside, and 
subsequently activate the adaptive immune system. This “albumin-hitchhiking” strategy 
represents a novel and efficient way for LN-targeted delivery of biologics, improving the 
therapeutic efficacy of cancer vaccines.  
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The aims of this dissertation are to further expand the scope of the “albumin-
hitchhiking” approach in immune modulation. We first evaluated the efficacy of three 
representative classes of lipid-modified CpG ODNs as vaccine adjuvants. Lipo CpG 
ODNs considerably drained to LNs more than unmodified CpG ODNs, while they 
appeared to be functionally compromised in in vitro immune activation. However, 
administration of lipo CpG class B and C ODNs, not lipo CpG class A ODN, with a protein 
antigen in mice led to improved antigen-specific CD8+ T cell responses and humoral 
responses relative to their parent compounds. We then evaluated the therapeutic efficacy 
of immunosuppressive ODN A151 and its lipid-modified form in inhibiting TLR9-mediated 
immune activation. The data showed that lipo ODN A151 was preferentially internalized 
by cells and accumulated in LNs in a larger magnitude compared to unmodified ODN 
A151. More importantly, prophylactic administration of lipo ODN A151, but not unmodified 
ODN A151, resulted in profound inhibition of immune responses challenged and induced 
by CpG-adjuvanted vaccines in mice. Next, we investigated the structure-dependent 
stability of lipid-modified amphiphilic polymers on red blood cells (RBCs). We revealed 
that longer lipid chain was correlated with more stable insertion on RBCs surface ex vivo, 
while shorter polyethylene glycerol (PEG) spacer favored amphiphiles with more lasting 
retention on RBCs in vivo. Furthermore, cationic amphiphiles constructed with cationic 
lipids demonstrated significantly improved retention kinetics on RBCs in vivo, evidenced 
by a 40-fold increase in circulation half-life relative to anionic counterparts. Finally, we 
discovered a novel adjuvant enhancer which potentiated the adjuvant activities of TLR7/8 
ligands in vitro and in vivo. The results showed that certain amphiphilic oligonucleotides 
could improve TLR7 ligand-induced NF-κB activation in the presence of albumin protein. 
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In vivo, administration of imiquimod-adjuvanted vaccine mixed with the structurally-
optimized amphiphilic oligonucleotide-based adjuvant booster induced a five-fold 
increase in the frequency of antigen-specific CD 8+ T cells and the production of antigen-
specific IgG in mice, compared to the same vaccine without adjuvant booster. Accordingly, 
lipid-functionalized oligonucleotide-based adjuvant booster could dramatically improve 
the immunogenicity of subunit vaccines. Collectively, lipid-functionalized oligonucleotides 
not only accumulate in LNs by hitchhiking endogenous albumin but also versatilely 
modulate the immune responses. Amphiphilic oligonucleotides may be broadly employed 
for the treatment of diseases involving the immune system, where the immune modulation 
is needed.   
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